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ABSTRACT 
 
Peptidoglycan Recognition Proteins (PGRPs) are a family of conserved proteins with 
antimicrobial activity in humans. PGRP-S is a 20kDA monomer with a poorly 
elucidated bactericidal mechanism. The aim of this project was to examine the 
genetic variation of the PGRP-S gene in the Sub-Saharan African 
immunocompromised population. DNA was extracted from the blood of HIV positive 
patients with and without active Tuberculosis as well as healthy controls. The coding 
regions of PGRP-S were amplified and subjected to direct automated sequencing. A 
wild type PGRP-S GST fusion protein was cloned, overexpressed, purified and used 
to determine protein-protein interactions as well as used in antimicrobial assays. 
Three polymorphic sites were noted in the population, as well as a stable variation in 
the genomic DNA from the mRNA sequence. One HIV positive Venda patient had a 
potentially novel non-synonymous mutation which would lead to a variant of protein 
with a reduced capacity to bind peptidoglycan. The variation of the genomic DNA to 
its corresponding nucleotide in the mRNA at position 80 may represent an example 
of RNA editing. The protein cloned had no discernable activity. Further studies with 
a larger population group and further analysis of the non-synonymous mutant protein 
may yield insight on the genetics and biochemistry of PGRP-S. 
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CHAPTER ONE 
INTRODUCTION 
1. Innate and Adaptive immunity 
 
Defence mechanisms against parasites and pathogens are of paramount importance to 
the survival of an organism. From the simplest to the most complex organisms have 
evolved some form of protection against unwanted organisms. This defence system is 
known as the immune system. Two systems of immunity exist: the ancient innate or 
natural immune system and the younger adaptive or acquired immune system. As the 
adaptive immune system occurs only in chordates (Pancer and Cooper, 2006), more 
interest has been placed on this system, assuming that the younger system developed 
to compensate for the perceived inadequacy of the more ancient innate immune 
system (Medzhitov and Janeway, 1997a). However, interest in the innate immune 
system was reawakened by the fact that the innate immune system directs the 
adaptive immune system (Fearon and Locksley, 1996) and arguments have been 
given about the importance of the innate immune system (Medzhitov and Janeway, 
1997a).  
 
There are several basic differences in the innate and adaptive immune system, as 
summarised in Table 1. The innate immune system is the first line of defence 
encountered by foreign bodies. It mounts an immediate maximal and non-specific 
response. The innate immune system is also capable of perfect differentiation of self 
from non-self due to the recognition system employed (Janeway, 1992). It is involved 
in most inflammatory responses as macrophages, mast cells, neutrophils and 
eosinophils all bear receptors of the innate immune system. These cells become 
activated during the inflammatory response (Janeway and Medzhitov, 2002). 
 
  The evolutionarily younger adaptive immune system is slower than the more 
generalised innate immune system. This lag in maximal response time is due to 
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immunoglobulin receptor rearrangement required by the adaptive immune system. 
This rearrangement leads to specificity towards a unique antigen and generates 
immunological memory, a hallmark of adaptive immunity. Adaptive immunity is 
therefore the system required for vaccine induced immunity. However, adaptive 
immunity is involved in allergy, autoimmunity and graft recognition. All this is due 
to the recognition system employed by the adaptive immune system (Janeway and 
Medzhitov, 2002).  
 
Table 1: Basic differences between the innate and adaptive immune systems, based 
on differences sited in Fearon and Locksley (1996) Medzhitov and Janeway (2001). 
Factor Innate Immunity Adaptive immunity  
Occurrence All eukaryotic organisms Chordates, Agnatha onward 
Specificity Non-specific, general response Specific, pathogen targeted 
response 
Action time Immediate, maximal response Delayed activation of effector 
molecules 
Memory No immunological memory generated Generation of immunological 
memory 
Receptors Germline encoded, no rearrangement 
needed  
Encoded in gene segments, 
rearrangement required 
Distribution Non-clonal Clonal 
Self 
discrimination 
Perfect discrimination of self from non-
self 
Imperfect, can lead to auto-
immunity 
Recognition Pathogen associated molecular patterns 
(PAMPS) recognised by Pathogen 
recognition receptors (PRRs) 
Details of molecular structure 
recognised by human leukocyte 
antigens, lock and key mechanism 
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2. RECOGNITION BY THE IMMUNE SYSTEM 
 
Adaptive immunity is an almost infinitely flexible system mediated by B and T-
lymphocytes. The Variable, Domain and Joining elements of their immunoglobulin 
and T-cell receptor genes are rearranged by the products of the Recombinase 
Activing (RAG-1 and RAG-2) genes. This rearrangement can result in the creation of 
as many as 1011 lymphocyte clones which express distinct antigen receptors 
(Thompson, 1995) 
 
B-lymphocyte receptors recognise protein, carbohydrate and simple chemical group 
conformations of native antigens, while most T-lymphocytes recognise protein 
antigens derived from peptides bound to cell surface proteins known as the Major 
Histocompatibility complex (MHC). Adaptive immune recognition is peptide based 
allows discrimination of a broader range of molecular structures and T-cells can 
recognise cytosol-derived non-glycosylated viral encoded proteins. This recognition 
strategy has been adopted to cope with the genetic variability of possible pathogens. 
However, this very strategy has resulted in the sacrifice of the ability to differentiate 
between potential pathogens and innocuous substances (Fearon and Locksley, 1996). 
 
The innate immune system recognises pathogens by conserved products of microbial 
pathogens that are not present in the host. Foreign objects, particularly pathogens, 
have molecular patterns that are strongly conserved in evolution and are unlikely to 
be replaced easily or rapidly. These Pathogen Associated Molecular Patterns 
(PAMPs) are distinctive features that will not be found in the host, allowing for 
perfect discrimination of self from non-self. Receptors of the innate immune system 
recognises signatures such as the prokaryotic cell wall components peptidoglycan and 
lipoteichoic acid, mannans from yeast and double stranded RNA found in viruses 
(Medzhitov and Janeway, 1997a).  
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PAMPs are recognised by a limited number of germline-encoded receptors called 
Pathogen Recognition Receptors (PRRs). There are three types of PRRs: Humoral 
proteins circulating in the plasma, transmembrane signalling or endocytic receptors or 
intracellular receptors. The recognition can either be direct, as with collectins which 
directly recognise and bind to pathogens with certain carbohydrate signatures. The 
receptor may also be triggered by the products of PAMP recognition, such as with 
classical complement pathway which is triggered by either the activation of antigen-
antibody-complement complex known as the C1 complex (Medzhitov and Janeway, 
1997b). 
 
Invertebrates function extremely well with only an innate immune system, as can be 
seen by the success of insects inhabiting non-sterile habitats. It has been suggested 
that the adaptive immune system developed, among many reasons,  due to the 
longevity of chordates and because the adaptive immune system is less metabolically 
costly (Rolff, 2007).  This highlights the importance of the non-clonal system of 
recognition, as a common hypothesis is that the adaptive immune system developed 
to overcome the inflexibility of non-clonal recognition. This hypothesis does not take 
into account that host evasion mechanisms employed by pathogens overcome 
recognition by specific clonal antigen receptors. Furthermore, it is likely that if a 
pathogen can avoid innate recognition, it can avoid adaptive recognition (Medzhitov 
and Janeway, 1997a).  
 
3. THE INNATE IMMUNE SYSTEM OF INSECTS 
 
Functionally, insects possess only an innate immune system. It has proved 
successfully to be sufficient for these organisms survive and proliferate. In long-lived 
insects such as cockroaches there are indications of specificity and immunological 
memory (Gillespie et al, 1997). Archetypal insect defence reactions involve physical 
barriers (the gut and integument), co-ordinated responses of haemocyte 
subpopulations and the induction of the synthesis of antimicrobial peptides and 
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proteins by the fat body, the organ analogous to the mammalian liver (Gillespie et al, 
1997). 
 
3.1 The immune response of Drosophila 
 
In Drosophila, as with most insects, the first line of defence is structural. The cuticle 
and integument act as physical barriers for pathogens. If an injury does occur the 
processes of coagulation and melanisation are induced. Melanisation occurs within 
minutes of injury and is mediated by crystal cells. Pathogens which do manage to 
escape these early defence mechanisms are phagocytosed by plasmatocytes and 
encapsulated. Encapsulation is a lamellocyte-mediated process whereby an 
overlapping sheath of haemocytes is formed around the target. (Lavine and Strand, 
2002). Antimicrobial peptides (AMPs) can be considered the last component of the 
insect’s innate response as it takes the longest to respond. They are released in two 
phases. The peptides are first expressed locally in barrier tissues, and later are 
distributed systemically (Khush and Lemaitre, 2000). 
 
Gram positive bacteria and fungi activate primarily the Toll pathway while anti Gram 
negative bacterial responses are mediated by the Imd pathway. This has the 
implication that Drosophila exhibits some specificity in its immune responses (Khush 
and Lemaitre, 2000). 
 
One of the critical questions of innate immunity was how an extracellular event such 
as an infection results in the intracellular production of antimicrobial peptides The 
missing key was the Toll receptor, a transmembrane protein which is linked to the 
extracellular compartment where signalling takes place. 
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4. THE TOLL RECEPTOR AND INNATE IMMUNITY IN INSECTS 
4.1 Characteristics of the Toll Receptor 
The Toll receptor was first described as a critical mediator in fly embryology as the 
determinant of dorsoventral polarity formation (Hashimoto et al, 1988). In 1995, the 
Toll receptor was shown to induce an immune response in cell culture (Rosetto et al, 
1995). Shortly afterwards, in 1996, the Toll pathway was demonstrated to be the 
cascade initiating antifungal defence in Drosophila (Lemaitre et al, 1996).  The 
control mechanisms leading to the synthesis of antimicrobial peptides were largely 
unknown until this discovery. In 1995 the same group had described the immune 
deficient (imd) mutation that impaired the inducibility of all antibacterial peptides in 
Drosophila. The mutation, however, did not affect the expression of the antifungal 
peptide drosomycin. This indicated that different pathways existed to induce 
antifungal and antibacterial peptide genes. The dorsoventral regulatory pathway was 
examined as the pathway had parallels to the cytokine-induced NFκB activation 
cascade found in mammals which is needed for the induction of a number of pro-
inflammatory mediators. Several of the proteins involved in the pathway leading to 
dorsoventral polarity and the activation of NFκB are homologous. The parallels in the 
signal transduction components were examined when kappa-B binding sites were 
observed in antibacterial peptide genes. It was demonstrated that any loss of function 
in the dorsoventral pathway impaired the induction of the antifungal peptide 
drosomycin. Mutations in the snake and easter genes, which function upstream of 
spätzle, the ligand for the Drosophila Toll receptor, did not affect drosomycin 
inducibility, highlighting that in immunity a different proteolytic cascade was 
involved in activating  spätzle  and triggering Toll signalling.  (Lemaitre et al, 1996).  
 
 Demonstrating the speed of progress in the field of Toll research, a human 
homologue of Drosophila Toll was described in 1997. The same study demonstrated 
that the Toll homologue was also involved in innate immunity (Medzhitov et al, 
1997). At the same time that Medzhitov’s human homologue was described another 
group had discovered a family of human receptors structurally related to Drosophila 
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Toll (Rock et al, 1998). Both groups began their search for homologues by using 
expressed-sequence tag databases. However, the human Toll (hToll) described by 
Medzhitov was identical to the receptor termed Toll-like receptor 4 by Rock and co-
workers (Rock et al, 1998). The nomenclature still stands and Toll-like receptor is 
often thought of as the “original Toll-like receptor” (Vasselon and Detmers, 2002). 
 
Toll is a type I transmembrane receptor containing a leucine rich ectodomain, which 
when deleted results in a constitutively active protein. The ectodomain also contains 
one or two cysteine rich regions. The intracellular domain of the receptor is 
homologous to a similar region in the intracellular region of the Interleuken-1 (IL-1) 
receptor. The IL-1 receptor leads to activation of the transcription factor NFκ-B and 
subsequently immune activation.  Due to this homology, that particular region of the 
intracellular domain is known as the Toll/IL-1 or TIR domain (Akira and Takeda, 
2004). 
 
TIR domains are not only found in Toll and Toll Like Receptors (TLR); rather an 
entire TIR superfamily exists. The members of the superfamily are extremely diverse, 
but are all involved in host defence or inflammation. Members of the TIR 
superfamily can broadly be divided into three subgroups. The first subgroup contains 
extracellular immunoglobulin domains. The second subgroup consists of proteins 
containing leucine rich repeats. The third subgroup consists of three members: 
MyD88, A46R and A52. These proteins are not receptors, but cytosolic adapter 
molecules (O’Neill, 2000). 
 
In Drosophila, several Toll-related proteins exist. These are Toll3 to 9, 18 wheeler 
(18W), Mst and STSDm2245. When comparing the conserved TIR domain Toll3 and 
4 share 79% identity, Toll and Toll 5 have 60% identity, as does 18w and Toll7. 
Toll6 is less related to the other Drosophila Tolls (Tauszig et al, 2000). The Toll-
related receptors are expressed in different tissues during development. Toll5, also 
known as Tehao, is structurally similar to Toll, and has the most similar expression 
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pattern. Toll8, also known as Tollo, has an expression pattern similar to 18W 
(Kambris et al, 2002). 
 
 Toll6 is expressed in the nervous system. Toll4 and 9 have a restricted expression 
pattern. After germ band extension Toll9 is no longer detectable in the embryo. The 
receptors are also differentially expressed in immune responsive larval tissues. Most 
Tolls are found in the fat body. In circulating blood cells Toll, 18W, and Toll8 are 
present, while 18W, Toll4, 8, and 9 are found in the lymph glands. Of the Toll related 
receptors it is known that 18W, Toll3, 4, 6, 7 and 8 do not activate NFκB related 
molecules or interact with the critical adapter molecule DmMyD88. (Kambris et al, 
2002).  However, it has been demonstrated that 18W, although dispensable for an 
immune response in adult Drosophila, is required for the induction of antimicrobial 
peptides in larvae (Ligoxygakis et al, 2002). Furthermore, Toll5 can activate the 
drosomycin promoter, although this has only been demonstrated in cell culture 
(Tauszig et al, 2000). The exception to the theory that Drosophila Toll-related 
receptors are not immune signalling molecules is Toll9. Toll9 has an ectodomain and 
TIR domain similar to mammalian TLRs (Bilak et al, 2003) and may use the same 
signalling pathway to activate immune genes (Bettencourt et al, 2004).  
  
 
5. TOLL LIKE RECEPTORS IN MAMMALS 
 
Toll-Like Receptors (TLRs) are a class of pattern recognition receptors found in 
mammals and are structurally related to the Drosophila Toll receptor. TLRs are 
defined as paralogues of Drosophila Toll. They share a tertiary fold called the Toll-
homology domain (TH) domain. The fold consists of a minimum of 128 amino acids.  
This domain is not only found in Toll and TLRs, but in the IL-1R family, plant 
disease resistance proteins and MyD88 factors. Toll and TLRs also share a 
characteristic Leucine Rich Repeat (LRR) ectodomain (Rock et al, 1998).  
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Rock and co-workers predicted that the existence of LRR indicated an affinity for 
Spätzle or another cystine-knot related factor (Rock et al, 1998). Indeed, there was 
some question as to whether Toll-like receptors were true PRRs. Drosophila Toll is 
not a true PRR as pattern recognition takes place upstream of Spätzle, which results 
in the cleavage and activation of the Toll ligand. No Spätzle-like protein has been 
described in humans. Although no direct crystallographic evidence exists of TLRs 
binding to a PAMP, the co-precipitation of TLRs and their PAMP ligands is the 
evidence currently used to define TLRs as true PRRs (Andersen-Nissen et al, 2007) 
 
There are currently eleven members of the TLR family known in humans, with the 
latest, TLR-11 being described in 2004.  Human TLRs can be divided into 5 
subfamilies; the TLR-2, TLR-3, TLR-4, TLR-5 and TLR-9 subfamilies. TLR-1, 2, 6 
and 10 constitute the TLR-2 subfamily, TLR-7, 8 and 9 make up the TLR-9 
subfamily. TLR-3, 4 and 5 are the only members of their subfamily. The families are 
based on evolutionary relationships but different subfamilies appear to have evolved 
to recognise specific ligands. Members of the TLR-2 subfamily are specific for 
lipopeptide PAMPs including zymosan and Peptidoglycan. Members of TLR-3 
family recognise double stranded RNA. LPS is recognised by receptors in the TLR-4 
family and members of the TLR-7 family nucleic acid and haem motifs (Roach et al, 
2005). There are a limited number of TLR receptors, yet they recognise a wide 
variety of PAMPs. The recognition repertoires of these receptors are increased by co-
operation between TLRs by dimerisation. The cytoplasmic domains of TLR 2 and 1 
or 6 associate to form dimers (Ozinsky et al, 2001).  TLR dimerisation occurs within 
members of the same subfamilies only. One of the classifications for subfamilies is 
that they recognize a similar kind of PAMP, hinting at divergent evolution (Roach et 
al, 2005). In 2001 Muzio and Mantovani proposed that TLRs could be classed in 
functional groups based according to expression patterns on a variety of blood cells. 
TLR1 is classed as ubiquitous, TLRs 2, 4 and 5 as restricted and TLR3 as specific 
(Muzio and Mantovani, 2001).  
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The wide distribution as well as the homo and heterodimerization of the receptors 
allows recognition of a diversity of ligands. TLRs initiate rapid and complex 
signalling pathways (Ozinsky et al, 2000). These pathways include the production of 
chemokines, pro-inflammatory cytokines and interferons and lead to an upregulation 
of co-stimulatory molecules. Most crucially, TLRs are an important bridge between 
the innate and adaptive immune systems (Clark and Kupper, 2005). 
 
6. THE INNATE IMMUNE SYSTEM DIRECTS ADAPTIVE IMMUNITY 
 
As mentioned previously, Toll is critical receptor in the innate immune response of 
Drosophila, as are the TLRs for mammals. However, TLRs are not merely critical 
innate receptors, but represent an interface between innate and adaptive immunity.  
As early as 1992 Charles Janeway jr. had argued that the adaptive immune system did 
not function in isolation because the delayed activity of this system due to receptor 
rearrangement was a timely process and if the adaptive immune system relied on 
specific antigen ligation only, the host would die before the adaptive immune system 
was mobilised. The immune system therefore did not function on a basis of either 
innate or adaptive mechanisms. Janeway argued, in addition to his PAMP theory, that 
a second signal provided by the innate immune system primed the adaptive response 
(Janeway, 1992). He was later proved correct as by 1996, it had been agreed that the 
innate immune system directs the adaptive (Fearon and Locksley, 1996).  
 
The theory proposed by Janeway (Janeway, 1992), in its logical simplicity, 
demonstrated that the idea that the innate and adaptive immune system functioned in 
isolation is a seriously flawed model. Not only are the receptors of the innate immune 
system more widespread and distributed on cells that would encounter an infection 
first, they are also represented by multiple protein families as opposed to receptors 
that are members of the immunoglobulin superfamily as the adaptive immune system 
is. The rearrangements of the receptors of the adaptive immune system are directed 
by somatic mechanisms, and as such, the T- and B-lymphocytes bearing the receptors 
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have an undefined and unpredicted specificity. The naïve lymphocytes cannot be 
driven to a specific function by a signal from its receptor alone. They require co-
stimulatory signals produced as a product of pattern recognition by the innate 
immune system. PAMPs induce endogenous signals that function as co-stimulators 
that activate T-cells. Innate immune signals also mediate the inflammatory response 
(Medzhitov and Janeway, 1997b). 
 
Innate immunity can direct the adaptive immune system by trans or cis actions. In a 
cis reaction, a covalent tag is added to an antigen so that it can be recognised by the 
adaptive immune system. An example of this is complement. The complement 
system is part of the innate immune system, which has a direct antimicrobial function 
in itself. The complement cascade is activated by microbial components and when 
activated C3b binds to nearby proteins or carbohydrates. C3b is then proteolytically 
processed to the C3dg fragment which can be recognised by CD21 (Cluster of 
Differentiation 21), a receptor expressed on B-lymphocytes and follicular dendritic 
cells (DCs) (Fearon, 1999). 
 
DCs are antigen presenting cells which develop in the bone marrow and migrate to 
tissues in an immature form. In the immature form they cannot serve as antigen 
presenting cells. DCs are induced to mature by inflammatory cytokines, LPS and 
Tumour Necrosis Factor. In maturing DCs CD80 and 87 are upregulated and Major 
Histocompability Complex (MHC) Class II complexes can be trafficked to 
appropriate intracellular complexes. Mature DCs then turn off their endocytotic 
functions and the expressed MHCII complexes represent the environment in which 
they encountered the antigen. The DCs then alter their adhesion proteins and 
chemokine receptors and migrate to secondary lymphoid organs where they can 
encounter antigen specific T-cells (Banchereau and Steinman, 1998). Distinct sets of 
TLRs are expressed on the immature DCs (Kadowaki et al, 2001), and as the 
recognition molecules for the maturation signals induce DCs maturation and 
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migration and consequently primes the adaptive immune reaction by stimulating T-
lymphocytes. This represents a trans reaction (Fearon, 1999). 
 
The nature of the acquired immune response is also directed by the innate immune 
system. The differentiation of precursor helper T-Cells (TH) into TH1 or TH2 cells is 
governed by the cytokine milieu. These instructive cytokines are produced early in 
infection and are produced by signalling cascade induced by PAMP recognition.  TH1 
type immunity is essential for the elimination of intracellular pathogens and the 
development of TH1 cells are driven by Interleukin 12 and Interferon γ. TH2 type 
immunity is required for mucosal parasite infections and IL 13 drives the 
differentiation of TH0 cells to TH2 (Banchereau and Steinman, 1998). Another 
important mechanism whereby the innate immune system directs the adaptive 
immune system is by antimicrobial peptides and proteins. 
 
7. ANTIMICROBIAL PEPTIDES AND PROTEINS 
 
The first invertebrate peptide antibiotics were characterised by Boman and colleagues 
in 1981. As the peptides were obtained from the silkworm Hyalophora cecropia the 
peptide was termed cecropin (Steiner et al, 1981). Since then numerous small, mainly 
cationic antibiotic peptides from a variety of structurally different families have been 
identified (Brown and Hancock, 2006). 
 
In mammals, many antimicrobial peptides (AMPs) are constitutively present in cells 
and stored in secretory granules, while others are induced by pro-inflammatory 
stimuli. AMPs tend to have large cationic patches on their surface which enable them 
to depolarize or pierce bacterial membranes which tend to be largely negatively 
charged (Oppenheim et al, 2003). 
 
AMPs can be broadly classified according to their charge; anionic or cationic. 
Anionic AMPs are structurally similar to the charge-neutralizing pro-peptides of 
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larger zymogens, which when synthesized are also antimicrobial. Cationic peptides 
occur in three principle categories: linear helical, linear proline rich or cysteine 
stabilized peptides with a β-sheet structure (Brogden et al, 2003). Mammalian AMPs 
belong to four structural classes. These are the β-sheet peptides stabilised by two to 
three disulphide bridges (protegrins, defensins), amphipathic α-helical peptides (the 
cathlecidin LL-37), loop peptides (Bovine neutrophil peptide) and peptides generated 
by proteolysis of larger proteins in the host (Yan and Hancock, 2001).  
 
7.1 Cathelicidins 
 
Cathelin is an inhibitor of Cathepsin L and a protein which lends its name to a family 
of antimicrobial proteins. These AMPs have a pro-region highly homologous to the 
cathepsin L inhibitor cathelin and are subsequently referred to as cathlecidins 
(Oppenheim et al 2003). Only one cathlecidin, LL-37, has been fully characterized. 
LL-37 is derived by the proteolysis of human CAP18 protein, and is only active after 
proteolysis (Golec, 2007).  It is a 37 amino acid peptide whose lack of cysteine 
residues results in a linear structure. The structure then adapts according to its 
environment, adopting a α helical structure in a hydrophobic environment and a 
largely random coil conformation in a hydrophilic environment. The peptide is 
induced by inflammatory or infectious stimuli and has activity against both Gram 
positive and Gram negativebacteria.  It also neutralises LPS, is chemotactic for 
neutrophils, monocytes and mast cells (in which it can also induce degranulation), 
and alters macrophage transcriptional regulation. It is also involved in re-
epithelisation of skin healing, wound vascularisation and also has anti tumour effects 
(De Smet and Contreras, 2005).  
 
7.2 Defensins 
 
Typical examples of cysteine stabilised peptides include the protegrins and the 
defensins. Defensins were initially isolated from rabbit and human neutrophils in an 
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attempt to characterise phagocyte-derived oxygen independent antimicrobial 
activities. About 50 defensins have been discovered. Vertebrate defensins are divided 
into Triple stranded antiparallel β sheets and cyclic peptides containing 6 cysteine 
residues. The two major classes,  α and β defensins, are antiparallel β-sheets (Yang et 
al, 2001).  
 
Mammalian defensins are cationic, non-glycosylated peptides with arginine as the 
primary catalytic residue. Their average molecular mass ranges from 3.5-6kDa and 
usually have three disulphide bridges due to the six cysteine residues characteristic of 
its class (De Smet and Contreras, 2005).  The α  or “classic” defensins contain  29-35 
residue amino acids and the disulphide bridges result in a triple stranded β-sheet 
structure with a β-hairpin loop containing the cationic charged molecules  (Ganz, 
2003). α-defensins are   found in the azurophilic granules of neutrophils (Yang et al, 
2001) and in humans are consequently referred to as Human Neutrophil Proteins 
(HNPs). HNP 1-3 are found not only in neutrophils, but B-and Natural Killer Cells as 
well. HNP 5 and 6 are referred to as Enteric defensins as they are found in granules of 
Paneth cells of the intestine. α-defensins are expressed as inactive pre-propeptides 
with the C-terminal part of the peptide accounting for the antimicrobial activity (De 
Smet and Contreras, 2005)   They are active against Gram negativebacteria, 
mycobacteria, fungi and enveloped viruses (Brogden et al, 2003). 
 
β-defensins are slightly larger than the classic defensins. They also have three 
disulphide bridges resulting in a β-sheet structure and a β-hairpin loop containing 
cationic molecules. The first β defensin isolated, human beta defensin-1 (hBD-1) is 
expressed in epithelial surfaces that interacts directly with the environment or 
microbial floras. hBD-2 is widely expressed and can be found in epithelial tissue, 
bone marrow and leukocytes. hBD-3 has been isolated from lesion psoriatic scales. 
hBD-3 is a broad spectrum antibiotic capable of killing a range of pathogenic bacteria 
and yeast, while hBD-1 and 3 are predominantly active against Gram 
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negativebacteria (Ganz, 2003). Besides antimicrobial activity, defensins have a 
variety of other biological functions. These include anti tumour activity, interference 
with cell signalling pathways, stimulation of cytokines, stimulation of cell 
proliferation, chemotaxis of immune cells and adhesion molecule expression (Garcia 
et al, 2001). 
 
7.3 Lysozyme 
 
Some antibacterial peptides are constitutively expressed in insects. One such protein 
is lysozyme, which hydrolyses β-1, 4 linkages between N-acetylglucosamine and N-
acetylmuramic acid in the peptidoglycan of bacterial cell walls. Insect lysozymes are 
14 kDa proteins with sequence similarity to chicken white lysozyme. In lepidopteran 
species lysozyme is expressed primarily in the fat body, while in the dipteran 
Drosophila melanogaster it is expressed in the midgut where it serves as a digestive 
enzyme rather than an antibacterial (Gillespie et al, 1997). 
 
Lysozymes are widely occurring enzymes found in many tissues and secretions, as 
well as in many organisms.  They are found in bacteriophages, bacteria, plants, and 
higher eukaryotes. Several classes of lysozyme exist; with the best known examples 
being the chicken type (C-type), Goose (G-type) and Viral type (V-type) (Bachali et 
al, 2002).  
 
Lysozyme (“lytic enzyme”) was discovered as a bacteriolytic factor by Alexander 
Fleming in 1922 (Gordon et al, 1979). The enzyme is believed to function by 
disrupting the mechanical integrity of the cell wall by degrading peptidoglycan. 
However, it has been proposed that T4 lysozyme may be more similar to other AMPs 
in that it causes membrane disruption as non-enzymatically active versions of the 
protein still maintain antimicrobial activity (Düring et al, 1999). 
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Lysozyme is believed to be a classical example of divergent evolution as they appear 
to have evolved from a remote common ancestor (Evrard et al, 1998). A family of 
proteins that are part of lysozymes’ evolutionary divergence are crucial in the 
recognition and defence against peptidoglycan. These are the peptidoglycan 
recognition proteins.  
 
8.  THE IMMUNE RESPONSE TO PEPTIDOGLYCAN: ANOTHER VITAL 
PATHOGEN RECOGNITION RECEPTOR ELUCIDATED 
8.1 The peptidoglycan recognition system 
8.1.1 Peptidoglycan, an archetypal PAMP 
 
Peptidoglycan, also known as murein, is a highly conserved bacterial cell wall 
component, found in all prokaryotes except the archaebacteria. In Gram positive 
bacteria, it typically constitutes a large portion of the cell wall, usually a 20 to 80 nm 
layer outside the plasma membrane. Gram negativebacteria usually have a 2-7 nm 
layer, making peptidoglycan 5-10 % of their wall weight. The polymer consists of 
two sugar derivatives, N-acetyl glucosamine and its lactyl ester N-acetyl muramic 
acid as well as several amino acids not found in proteins (Scheffers and Pinho, 1995).  
The basic structure of peptidoglycan and the point of variation that separates 
diaminopimelic type peptidoglycan (found in Gram negatives) from Lysine-type 
peptidoglycan (found in Gram positives) is illustrated in Figure 1.  
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Figure 1: The structure of peptidoglycan. Green represents the N-acetylglucosamine 
(NAG) residue. Blue represents the lactyl ester of NAG, N-acetyl muramic acid 
(NAM). Purple represents the tetrapeptide chain (Based on information in Scheffers 
and Pinho, 1995). 
 
 
Due to its highly conserved nature and simplicity of its structure, peptidoglycan is an 
ideal motif for recognition by the innate immune system. It can be considered an  
 
archetypal PAMP, and is recognised by a diverse array of PRRs. As such, several 
innate mechanisms are in place to respond to peptidoglycan detection. It was studying 
one of these systems, the prophenoloxidase system that lead to the discovery of 
family of lysozyme-related proteins required for the recognition of peptidoglycan.  
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8.1.2 The Prophenoloxidase cascade 
 
The Prophenoloxidase (ProPo) cascade is an efficient mechanism of recognising non-
self in invertebrates. This system can recognise and respond to concentrations of 
lipopolysaccharide, β-1, 3 glucans and peptidoglycan as low as picograms per litre. 
The ProPo cascade causes the parasite to blacken in the haemolymph. This is due to 
the process of melanisation, the deposition of melanin around an encapsulated object 
at the site of infection (Söderhall and Cerenius, 1998).  
 
Phenoloxidase (monophenyl L-dopa: oxygen oxidoreductase) is found in the 
haemolymph or coelom of many invertebrate groups, found in both protostomes and 
deuterostomes. The enzyme catalyses the oxidation of both mono and diphenols to 
quinones. The quinones then non-enzymatically polymerise to form melanin 
(Söderhall et al, 1998). Melanisation plays a role in defence through its action in 
wound healing. Phenoloxidase also causes the cuticle to harden by sclerotinisation 
(Gillespie et al, 1997). The intermediates formed during the melanisation process, in 
addition to the melanin are toxic to micro organisms. In its native form 
Prophenoloxidase (ProP) can exist as an oligomer. The purified monomer of ProP of 
several invertebrates has a mass of 70-80 kDa. After cleavage the monomer has a 
mass of 60-70 kDa. The cleavage of ProP results in the activation of the enzyme. This 
activation is mediated by the action of several serine proteases. The activating serine 
proteases isolated from crayfish, silkworm and fruit fly are proteins of about 30 kDa. 
The enzyme requires cleavage, i.e. it remains inactive, partly as a regulatory measure 
as the intermediates of the cascade are toxic. As such the ProP zymogens are located 
in blood cell vesicles (Cerenius and Söderhäll, 2004). As is typical of the innate 
immune system, the cascade is initiated by pattern recognition by a PRR, which 
occurs upstream of the activating serine protease cascade. The recognition process 
and the subsequent production of melanin by the Prophenoloxidase cascade is 
schematically represented in Figure 2. 
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Figure 2: Schematic description of the Prophenoloxidase cascade which leads to 
melanisation. PGRP, Peptidoglycan recognition protein; βGRP, β-Glucan recognition 
protein; Pro-ppA, Pro-Prophenoloxidase activating enzyme; ppA, Prophenoloxidase 
activating enzyme. This diagram is based on descriptions in Söderhäll and Cerenius 
(1998), Cerenius and Söderhäll, (2004) and Lavine and Strand, (2002). 
 
8.1.3 Purification of a PGRP from Bombyx mori  
 
Studies of the ProP cascade led to the discovery of the original recognition receptor 
for peptidoglycan in the silkworm Bombyx mori. The fungal cell wall component β-
1,3 glucan and the bacterial cell wall component peptidoglycan were known to trigger 
the ProP cascade. As the innate immune system works on pattern recognition, it was 
assumed by Yoshida and co-workers (1996), that pattern recognition receptors existed 
for these components. They proposed that these receptors, which they termed β-1,3 
glucan  recognition protein (βGRP) and peptidoglycan recognition protein (PGRP),  
exist to recognise β-1,3 glucan  and peptidoglycan respectively. Their proposed 
βGRP was isolated in the silkworm, cockroach and crayfish. The group then 
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proceeded to isolate PGRP from Bombyx mori. They demonstrated that Silkworm 
PGRP is specific, binding only to peptidoglycan and not β-1,3 glucan or chitin. The 
confirmation of the existence of PGRP showed that the ProP cascade had two points 
of initiation, β-1,3 glucan and peptidoglycan recognition (Yoshida et al, 1996).  
 
8.2 A family of Drosophila and human PGRPs  
The discovery of PGRP in Bombyx mori began a search for homologous proteins in 
other organisms. Drosophila PGRPs, in contrast to previously discovered PGRPs, 
had two different classes of the protein, as opposed to the single class in the silkworm 
The first class, consisting of seven small, exported proteins, are similar to all PGRPs 
found in Bombyx mori and Trichoplusia ni. The second class of the proteins are long 
transcripts, and appeared to be membrane proteins. The PGRPs are widespread across 
the genome; over eight chromosomal loci on the three major chromosomes of the fly 
(Werner et al, 2000). 
 
The short PGRPs consist of a PGRP domain preceded by a signal peptide, which was 
predicted to be processed so that the mature protein consists only of the PGRP 
domain. This particular class of proteins contains the members PGRP-SA, PGRP-
SB1, PGRP-SB2, PGRP-SC1B, PGRP-SC2 and PGRP-SD. The long PGRP genes 
give rise to longer transcripts which often have several splice forms. This class does 
not encode a typical signal peptide. Three of the long transcripts, PGRP-LA, PGRP-
LC and PGRP-LD have a predicted transmembrane region. PGRP-LE has a highly 
charged N-terminal domain connected to the PGRP domain, but has no export signal 
or transmembrane region. PGRP-LB encodes only a PGRP domain attached to a 
relatively long 5’ untranslated region (Werner et al, 2000). 
 
Drosophila PGRPs have differing expression during the lifetime of the fly. During 
development most PGRPs are detectable in all post embryonic stages. PGRP LD and 
LE are highly expressed in 0-5 hour embryos. PGRP-SB2 is expressed exclusively in 
the pre-pupae. After immune challenging with both Gram positive and Gram  
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Negative bacteria, PGRP LB, SA, SC2 and SD were strongly expressed. PGRP-LB is 
the only inducible long transcript. The inducible genes were found to be expressed in 
the fat body. PGRP-SC and SC2 showed high constitutive expression. Of the short 
PGRP genes, only PGRP SC was constitutively expressed at high levels in the gut 
(Werner et al, 2000). 
 
In 2001 Liu et  al. described the family of four human PGRPs. The 576 amino acid   
PGRP-L is found on chromosome 19, as is the 196 amino acid PGRP S. PGRP Iα 
and Iβ, 341 and 343 amino acids respectively, are found on chromosome 1. ). 
Western Blot analysis showed PGRP L, Iα, Iβ and S to be 65, 38, 40 and 24 kDa 
peptides respectively. . All PGRPs bind peptidoglycan directly, as demonstrated by 
their ability to bind peptidoglycan bound to agarose. However, the strength of binding 
is not equal. While PGRP S, L and Iα bind peptidoglycan with high affinity, PGRP Iβ 
binds the molecule with a low affinity. This was speculated  indicate that PGRP Iβ 
may bind another unknown ligand, or need other ligands for high affinity binding 
(Liu et al, 2001). 
 
The C-terminal regions of all four PGRPs are highly conserved, containing three 
PGRP domains. PGRP Iα and Iβ have an additional PGRP domain, designated 
domain IV, in the N-terminal half. This additional domain is 89% similar to PGRP 
domain II (Liu et al, 2001). The PGRP domain is also known as the T-phage 
lysozyme homology domain (Kibardin et al, 2003). At present there are 328 PGRP 
domains in 284 proteins in the Simple Modular Architecture Research Tool 
(SMART) database, including Drosophila and mammalian PGRP as well as T7 
lysozyme (Schultz et al, 1998; Letunic et al, 2004).  A landmark study by Lazzaro 
and co-workers demonstrated that immune competence in wild flies is driven by 
polymorphisms in 16 innate immunity genes. PGRPs were of these genes, with 
polymorphisms in the PGRP domain leading to immunocompetence (Lazzaro et al, 
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2004). This demonstrates the critical role of the PGRP domain in the successful 
functioning if the protein.  
The C-terminal region of all insect and mammalian PGRPs contains several highly 
conserved residues.  Between the second and third domains two cysteines, an 
arginine, a glutamine, and a histidine residue are found. Conserved asparagine, 
glycine, isoleucine, phenylalanine and proline residues are found between domain I 
and II (Liu et al, 2001). This later proved to be important for protein structure and 
function, especially when the crystal structure for PGRP-S was elucidated (Guan et 
al, 2005).  
8.3  PGRP-S/PGLYRP-1 
8.3.1 PGRP-S in Drosophila 
 
Short PGRPs in Drosophila are usually assigned three major roles; the activation of 
the Toll pathway (PGRP-SA) (Michel et al, 2001), activation of the Pro-Phenol 
oxidase cascade (Yoshida et al, 1996) and direct enzymatic activity (PGRP-SC1 and 
PGRP-SA), with PGRP-SC1 being an N-acetylmuramoyl-L-ala amidase and PGRP-
SA being a carboxypeptidase (Chang et al, 2004). Recently, PGRP-SB1 was 
described as an N-acetylmuramoyl-L-ala amidase as well, and this activity gives it 
direct antibacterial activity, particularly against Bacillus megaterium. Its mode of 
action is therefore different to vertebrate PGRPs.  (Mellroth and Steiner, 2006).  
Furthermore, short PGRPs were also involved in the regulation of the IMD pathway. 
Bischoff and co-workers described that PGRP-SC1a and b deficient flies had an over 
activation of the IMD pathway presumably by degrading peptidoglycan before it 
reaches PGRP-LC and PGRP-LE (Bischoff et al, 2006).  
 
PGRPs have a significant homology to bacteriophage T7 lysozyme, making it part of 
the N-acetyl muramoyl-L-alanine amidase superfamily. This enzyme hydrolyses the 
bond between the N-acetylmuramoyl group in the glycan strand and the L-alanine 
stem peptide in peptidoglycan. It was reported by Mellroth and colleagues that a 
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Drosophila PGRP, PGRP-SC1B can degrade peptidoglycan to less 
immunostimulatory products. However, the degradation takes place to different 
degrees. PGRP-SC1B degrades the direct cross link between stem peptides, and 
peptidoglycan containing meso-diaminopimelic acid is the most resistant degradation 
(Mellroth et al, 2003).  
 
Five conserved amino acids are required for the enzymatic activity of T7 lysozyme. 
PGRP-SC1B has four of those five residues. The fifth, a threonine 128 substitution 
for lysine, is consistent with a reduced lysozyme activity. Based on this requirement, 
there are five potentially enzymatic PGRPs; PGRP-SB1, SB2, SC1A, SC2 and LB. 
Indeed, PGRP-SC1B has enzymatic activity (Mellroth et al, 2003) as does PGRP-
SB1 (Mellroth and Steiner, 2006). Enzymatic PGRPs differ from PGRPs with a 
purely receptor function by a serine for cysteine 130 substitution, thus removing one 
of three zinc ligands making them inactive enzymes. The cysteine residue can serve 
as a marker for PGRP function; the presence of a cysteine being a marker for 
enzymatic PGRP and the absence of a cysteine residue indicative of a receptor type 
PGRP. This protein is the first example of a eukaryotic N-acetyl muramyl 
transamidase (Mellroth et al, 2003). 
 
PGRP-SA adopts a fold unique to the PGRP-S structure. This includes a mixed strand 
beta sheet and three alpha helices forming the protein core. Two additional β-strands  
are found at the N-terminus. PGRP-SA as well as PGRP-LB has a conserved L-
shaped groove also found in T7 lysozyme. The groove is thought to represent the 
peptidoglycan binding site. Three highly conserved residues; Cys48, Tyr76, and 
Thr156 are essential for peptidoglycan recognition in Drosophila PGRP. It is known 
that a mutation of Cys48 abolishes the ability of PGRP-SA to activate the Toll 
receptor (Michel et al, 2001). This cysteine is involved in a disulphide bond with 
Cys54 at the edge of the L-shaped groove. This disulphide bond may be needed for 
the structural integrity of the groove (Reiser et al, 2004). 
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The discovery of the link between PGRP and Toll activation has been an interesting 
journey. In a screening of genes involved in the Drosophila immune pathway, 
Reichhart and co-workers isolated a fly line with a reduced ability to induce 
drosomycin, i.e. a loss of function Toll mutant, in response to Gram positive bacteria 
only. The mutation was called semmelweis, (seml) after the Hungarian physician 
Ignaz Semmelweis. Seml was the first mutation discovered which abolished Toll 
activation for Gram positive bacteria only. Seml was shown to act upstream of Toll as 
drosomycin transcription in a gain of function seml double mutant could induce 
drosomycin peptide expression. Seml does not play a role in dorso-ventral axis 
formation, in contrast to Toll pathway mutants, homozygous seml females are always 
fertile (Michel et al, 2001). 
 
The seml mutation was mapped to a gene coding for PGRP-SA, specifically to a 
single guanine to adenine mutation at base pair 74 resulting in a cysteine 80 to 
tyrosine mutation. The mutation lies in the PGRP domain. The seml phenotype was 
rescued by the injection of wild type haemolymph into recipient flies. This marked 
PGRP-SA as a circulating haemolymph protein (Michel et al, 2001).  
 
A complementary mutant affecting only the fungal branch of Toll activation was 
found as follows. The necrotic (nec) gene encodes three serine proteases inhibitors of 
the serpin family. Mutations in this gene results in necrotic areas on the epidermis, 
manifesting as brown spots along the body and leg joints. One of these genes, 
Spn43Ac, can rescue this mutant phenotype. Nec mutants have constitutive 
expression of the antifungal peptide drosomycin, but not the antibacterial peptide 
cecropin A1. This implicates Spn43Ac in the Toll, but not imd pathway, as 
drosomycin is an end product of the Toll pathway and cecropin A1 of the imd 
pathway. Introducing the serpin into nec mutants prevented the constitutive activation 
of the Toll pathway. The serpin is therefore a negative regulator of the Toll pathway. 
The 60 kDa protein is found in the haemolymph of the fly. Spn43Ac regulates Toll as 
an inhibitor of one of the serine proteases required for the cleavage and activation of 
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the Toll ligand Spätzle. Nec flies do not have the cleaved form of Spätzle after 
immune challenge, yet have no developmental defects (Levashina et al, 1999). 
 
If a serpin deficiency results in the constitutive expression of the Toll pathway, a 
serine protease is necessary for the regulation of Toll activation. What is the target 
protease for Spn43Ac? The same group who described the nec mutation discovered a 
suppressor mutation in the nec flies. This mutation was named Persephone (psh). 
Nec:psh double mutants had a lifespan comparable to wild type flies, as well as 
normal Toll and Imd functioning. The psh mutation was mapped to a region encoding 
two serine proteases. The serine protease Persephone was the first identified 
component of the serine protease cascade responsible for the activation of Toll during 
an immune challenge. Furthermore, the psh mutation was the first mutation described 
which impairs fungal induced drosomycin induction (Ligoxygakis et al, 2002). 
   
 
8.3.2 Mammalian PGRP-S: the discovery of PGRP function   
 
Although Drosophila is a useful model organism for many systems, caution must be 
exercised when drawing parallels to function in humans. This is particularly evident 
in the immune system. The Toll and TLR pathways are highly conserved, but TLRs 
serve no apparent developmental role in mammals. However, one of the first 
functions postulated for the TLR family was that it may be involved in the 
development of vertebrate embryos (Rock et al, 1998). It is now generally accepted 
that TLRs have no developmental functions in vertebrates (Beutler, 2004).  
 
When PGRPs were first discovered it was confidently declared that only PGRP-S was 
a signalling molecule and other human PGRPs were cytoplasmic. The bold statement 
was made on a structural modelling prediction (Liu et al, 2001). This was later 
disproved by a potentially damaging article by Xu et al (2004), which claimed that 
PGRP-L may be dispensable for innate immunity. This was largely due to the 
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examination of the behaviour of macrophages in PGRP-L null mice, even though the 
gene is not expressed in macrophages. The experiment appeared to rely on the 
assumption that PGRP in mammals also behaved as a signalling molecule. However, 
the same study found PGRP-L as well as PGRP-Iα and β to be soluble, disproving the 
well postulated structural model (Xu et al, 2004). Furthermore, with PGRPs proving 
to be antimicrobial proteins and not signalling molecules, in contrast to the 
multifunctional Drosophila PGRPs, it would be wise to be conservative when 
drawing comparisons between the immune systems of Drosophila and humans. It is 
important to bear in mind the multifunctional nature of Drosophila proteins (e.g. 
PGRP and Toll) before assuming that the mammalian homologues will behave in the 
same manner.  
 
Short PGRP has always had a special position in PGRP research. The PGRP 
discovered in Bombyx mori (Yoshida et al, 1996) was a short PGRP, and the first 
mammalian PGRP discovered and cloned was PGRP-S (Kang et al, 1998). PGRP-S is 
described as being originally identified and characterised by Kiselev et al in 1998  
under the name of Tag7(Cho et al, 2005), at around the same period that the Steiner 
group discovered PGRP-S by initial differential display studies on Trichoplusia ni. 
This may give the false impression that PGRP-S and Tag 7 is the same molecule, but 
this will be examined more closely later in a discussion of the Tag 7 molecule. 
PGRP-S is the protein that leads to the discovery of the antimicrobial nature of the 
human PGRP family.  
 
The path to the elucidation of PGRP function began when Roman Dziarski, Håkan 
Steiner and co-workers described that PGRP-S deficient mice had an increased 
susceptibility to infection with non-pathogenic bacteria, but mice with wild-type 
PGRP-S were still equally susceptible to infection by pathogenic bacteria (Dziarski et 
al, 2003). This was the basis of the work leading to the definition of PGRP-S as an 
antimicrobial protein. Based on the aforementioned study, Dziarski proposed that 
certain bacteria are non-pathogenic due to the action of PGRP-S (Dziarski et al, 
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2003). The work demonstrating the bacteriostatic and bactericidal activities of Bovine 
Oligosaccharide-binding protein towards both Gram positive and Gram 
negativebacteria (Tydell et al, 2002) as well as studies by Cho et al on the immune 
function of PGRP-S demonstrated a few critical basic facts of PGRP-S function. 
Firstly, they demonstrated that PGRP-S was capable of binding both Lys and DAP-
type peptidoglycan and thus had broader ligand specificity than other mammalian 
PGRP-S molecules. They also demonstrated the dose dependent inhibition of S. 
aureus and E. coli by radial diffusion assays, and that the inhibition mechanism 
required peptidoglycan -dependent binding. The synergistic effect of PGRP-S with 
lysozyme was also demonstrated. The group also highlighted the fact that PGRP-S is 
microbicidal to organisms containing no peptidoglycan (Cho et al, 2005). The 
antimicrobial nature of PGRP-S had been determined and from the onset, it proved to 
be an intricate and complex system. 
 
Shortly after the definitive description of PGRP-S’ antimicrobial function, a 
landmark study described that all human PGRPs are actually antimicrobial and 
constituted a novel class of human bactericidal proteins. Lu et al (2006) demonstrated 
several critical facts about human PGRPs. Firstly, all human PGRPs had bactericidal 
activity. Both pathogenic and non-pathogenic bacteria were killed by PGRPs. 
Secondly, PGRPs functioned as disulphide linked dimers with different specificities. 
PGRP Iα and β as well as PGRP Iαβ heterodimers were highly bactericidal towards 
Bacillus subtilis, but not Lactobacillus acidophilus. Listeria monocytogenes was 
sensitive to PGRP I α and β homodimers but not heterodimers (Lu et al, 2006) 
 
PGRP-S is highly bactericidal to L. acidophilus, but not to L. monocytogenes. Normal 
flora such as Staphylococcus epidermis, Micrococcus luteus, Enterococcus faecalis, 
and Streptococcus agalactiae were not sensitive to PGRP killing. The spectrum of 
PGRP activity corresponded to the localisation of PGRP and thus indicated that 
PGRPs may play a role in the existence of normal flora. The bactericidal activity of 
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PGRPs is dependent on interaction with peptidoglycan rather than membrane 
permeabilization (Lu et al, 2006).  
 
All mammalian PGRPs bind peptidoglycan and have a direct antibacterial function. 
In 2006 human PGRPs were declared a new class of bactericidal proteins (Lu et al, 
2006). They are significantly different to other known AMPs, differing in structure, 
expression and known mechanism of action. They are of the largest known 
antimicrobial peptides, indeed, with the smallest (PGRP-S) being a 24kDa monomer, 
they are proteins rather than peptides. Vertebrate AMPs usually kill by traversing the 
bacterial cell wall and membrane permeabilization. peptidoglycan-lytic enzymes 
destroy the integrity of peptidoglycan and thereby induce osmotic lysis.  Cell wall 
targeting antibiotics inhibit peptidoglycan synthesis. The kinetics of PGRP bacterial 
killing resembles that of the cell wall targeting antibiotic Penicillin, and unlike 
AMPs, do not target the membrane. There are two proposed mechanisms for the 
antimicrobial activity of PGRPs. As they strongly bind peptidoglycan, they could 
prevent cell wall synthesis. The second mechanism is killing by enzymatic digestion 
of peptidoglycan. This, however, is unlikely as only PGRP-L has amidase activity.  
(Lu et al, 2006). The exact mechanism of antimicrobial activity of these proteins is 
thus still largely unknown. 
 
Lu et al also demonstrated the importance of glycosylation and divalent cations for 
PGRP function. N-glycosylase treatment completely negated PGRP function. They 
also proposed that PGRPs previously described as only bacteriostatic were only 
behaved as such because they were purified without calcium ions (Lu et al, 2006). All 
four PGRPs required zinc ions for bactericidal activity. Calcium can partially replace 
zinc, but only for the killing of Gram positive bacteria (Wang et al, 2007).  
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8.4 Tag 7 
 
In 1998 a novel murine cytokine, Tag7, was cloned. The soluble form of the protein 
triggered apoptosis in murine L929 lines. The protein was assigned an immune 
function as it was constitutively expressed in lymphoid and haemopoietic tissues, but 
the authors could not find any significant homologous proteins in the databases of the 
time (Kiselev et al, 1998). A murine Tag7-like protein (GenBank accession no: 
AF193843) was fond to have 99.6% identity to murine PGRP (GB: AF0768421) and 
99.3% identity to murine Tag7 (GB: X86374), suggesting that Tag7 may be a form of 
PGRP (Rehman et al, 2001).  
 
It was reported in 1998 that shifts in the reading frame of murine Tag7 made it 
identical to murine PGRP. Tag7 is therefore a short PGRP (Kang et al, 1998). Tag7 
has since demonstrated interesting properties not seen before in short PGRPs. Murine 
PGRP is intriguingly different to that of humans. As reported by Rehman the 
molecule they termed Tag7/PGRPS, as it coded identical transcripts, was involved in 
sleep regulation in rats. Sleep deprived rats had significantly increased mRNA levels 
of Tag7/PGRPS. (Rehman et al, 2001). In 2008 it was demonstrated that murine 
PGRP-S was upregulated by NF-κB in a relA dependent manner (Lang et al, 2008). 
The original purpose of the study was to determine the role of PGRP-S in cerebral 
ischemia, but the most finding of the study was the first report of a regulation 
mechanism of a mammalian PGRP. These observations have only been made in 
murine models, and again it would be wise to exercise caution before extrapolating 
these findings to humans.  
 
Tag7  also forms a stable cytotoxic complex with Heat Shock Protein 70. It was 
suggested that PGRPs may play a role in anticancer defence (Saschenko et al, 2004). 
This was confirmed by a study demonstrating that transfection with Tag7 cDNA 
decreased oncogenicity of mammary gland adenocarcinoma in immunodeficient 
animals (Larin et al, 2004). The last reported results on Tag7 trials stated that phase 
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I/II trials of gene therapy on human patients with disseminated melanoma and 
metastatic renal cell carcinoma was underway (Moiseyenko et al, 2005).   
 
 
8.5 Potential clinical implications for PGRP-S 
 
Thus far, the study of PGRP-S, indeed of the entire family, has been limited to 
examining its’ biological role and functioning. Very little has been published about 
human PGRPs since the two landmark discoveries marking them as antimicrobial 
proteins (Lu et al, 2006) with a requirement for cationic molecules to function (Wang 
et al, 2007). PGRP-Iα and β have been implicated in psoriasis biology (Sun et al, 
2006) but to date clinical data about PGRPs has been sparse.  The first official 
clinical study involving PGRP-S was published this year. Rohatgi et al reported that 
an increased serum level of PGRP-S was associated with older age, and diabetic, 
hypertensive, actively smoking, and hypercholestrolemic caucasians. These patients 
also had a history of myocardial infarctions and generally had a higher body mass 
index (Rohatgi et al, 2008). These are all intriguing factors, but the authors appear to 
ignore the fact that PGRP-S is an antimicrobial protein. They do not mention 
anything about the health of their patients with reference to potential infections that 
may account for increased serum levels of the protein at the time of sampling. They 
also describe PGRP-S as a PGN scavenger and receptor, according to the work of 
Cho et al, 2005 and Liu et al in 2000. The landmark work of Liu et al of 2006 
describing the molecule as an antimicrobial protein is not cited at all. The results of 
their findings are noteworthy nonetheless and determining the nature of the 
relationship of PGRP-S to arthrosclerosis is a possible area of study, particularly as 
initial northern blots determining the tissue expression of PGRP mRNA did not show 
PGRP-S to be expressed in the heart (Liu et al, 2001).  
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9. Aims and Objectives 
 
There are clearly many unanswered questions about PGRPs. As antimicrobial 
proteins they have potential for future therapeutics. However, their mechanisms of 
action are poorly understood. Have all their ligands been elucidated? Do they interact 
with other proteins? How are PGRPs distributed in the population? The aim of this 
study is to characterise the genetics and biochemistry of PGRP-S by asking basic 
questions. What genetic variation exists in the PGRP-S gene of the South African 
population? Does genetic variation lead to different forms of the protein? The 
biochemical analysis aims to determine the nature of the interaction of PGRP-S with 
other proteins and to characterise its’ antimicrobial effect.  
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CHAPTER TWO 
 
MATERIALS AND METHODS 
 
2.1 INTRODUCTION  
 
This project involved the analysis of materials obtained from human subjects. This 
material was gathered according the principles set up by the Ethics committee of the 
University of the Witwatersrand, ethics clearance number R34/39.  All patients were 
fully informed of what they would be subjected to, both by a formal letter and by 
trained staff of the Johannesburg General hospital. An example of the ethical consent 
form can be found in Appendix A. Three groups of patients were analysed; HIV 
positive (defined as patients at on antiretroviral therapy), HIV and TB positive 
(patients on antiretroviral therapy with an active tuberculosis infection) and healthy 
patients not on antiretroviral therapy. The aim of the groupings was to determine 
whether the immunocompromised population had an increased amount of variation in 
the PGRP-S gene. The subjects constituted a sample of the appropriate group at the 
hospital. The patients’ family history as well as a brief medical history was collected 
where possible. 
 
2.2 METHODS  
 
2.2.1 NUCLEIC ACID ANALYSIS  
 
2.2.1.1 RNA Extraction 
 
Fresh blood was collected from patients of the Anti-Retroviral clinic at the 
Johannesburg General Hospital. Control samples were obtained from healthy 
volunteers from the University of the Witwatersrand. Once ethical consent was 
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obtained from the individual, blood was drawn into 5ml EDTA tubes. The blood was 
processed within 8 hours of collection to ensure the integrity of the RNA. 
 
Total RNA was extracted from whole blood using the QIAamp RNA Blood Mini kit 
according to manufacturer’s specifications (Qiagen) as detailed in the appendix table 
RNA was quantified by using a Nanodrop® spectrometer. The integrity of RNA to be 
used in subsequent experiments was determined by formaldehyde agarose gel 
electrophoresis as described by Sambrook et al (1989).  
 
2.2.1.2 DNA Extraction 
 
Genomic DNA was extracted from whole blood using QIAamp DNA Blood Midi kit 
according to manufacturer’s protocol (Qiagen, South Africa), as detailed in the 
appendix.  
2.2.1.3 Amplification of coding regions of PGRP-S 
 
 
Figure 3: Schematic diagram of the amplification of PGRP-S.  
 
The primers for the amplification of Exon 1 were designed manually to bind 50 base 
pairs outside the coding region to yield a 400bp product. Due to the 60bp intron 
separating Exon 2 and 3, the two regions were amplified as a single product with 
primers binding outside the coding regions for Exon 2 and 3. The coding regions of 
PGRP-S were amplified using the polymerase chain reaction using the Perkin Elmer 
GeneAmp PCR system 2400. 
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Exon 1 was amplified using the following primers:  
PGRP-S Exon1 Forward: 5′-GGCGCTCCTAGCGGTCTC-3′ 
PGRP-S Exon 1 Reverse: 5′- ACTTGCACACCTTTGCCTCT-3′.  
The primers were synthesised by Inqaba Biotec. The reaction mixture for Exon 1 
contained 0.5U of Taq polymerase (New England Biolabs), 10mM dNTP (Inqaba 
Biotech), 1.2mM MgCl2, 1µM of forward and reverse primer, 50-500ng of template 
in a final volume of 50µl. 
 
The amplification consisted of a 5 minutes pre-denaturation at 94oC, followed by 
thirty five cycles of 94oC for 30 seconds, 60oC for 30 seconds and 72oC for thirty 
seconds. This was followed by a final extension at 72oC for 7 minutes. 
 
Exon 2 was amplified using the following primers: 
PGRP-S Exon 2 Forward: 5’- TGGGAAATTAACGGGTGAGA -3’ 
PGRP-S Exon 3 Reverse: 5’- TGAGGAACACATTTTGAGCTACAT -3’. 
The reaction mixture for Exon 2 contained 0.5U of Taq polymerase (New England 
Biolabs), 10mM dNTP (Inqaba Biotech), 1.0mM MgCl2, 1µM of forward and reverse 
primer, 50-500ng of template in a final volume of 50µl. 
The amplification consisted of a 5 minutes pre-denaturation at 94oC, followed by 
thirty five cycles of 94oC for 30 seconds, 54oC for 30 seconds and 72oC for thirty 
seconds. This was followed by a final extension at 72oC for 7 minutes. 
2.2.1.4 Cleanup of PCR amplicons 
 
A 1% agarose gel was prepared in TAE buffer containing ethidium bromide 
(0.05mg/ml). DNA electrophoresis loading buffer was added to an aliquot of PCR 
amplicons and electrophoresed for 60 minutes at 100V. The amplicons were sized 
using the GeneRuler™ 100bp plus ladder as a molecular weight marker. Amplicons 
that could be clearly visualised when 5µl was electrophoresed were used for 
subsequent sequencing reactions.  Successfully amplified products were 
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electrophoresed on a 1% agarose gel without ethidium bromide. The 
electrophoretogram was washed in a 1/10 000X solution of SyBr Gold (Invitrogen). 
The gel was viewed on Dark viewer (Clare Chemical Research) and the bands 
excised. This prevented any potential muatation inductions by the intercalation of 
ethidium bromide and any ultra violet induced damage. The fragment was cleaned up 
using the GenElute™ Gel extraction kit (Sigma).  
 
2.2.1.5 Sequencing of PCR amplicons 
 
PCR amplicons were prepared for sequencing using the BigDye® Primer Cycle 
sequencing kit,  and sequenced on an ABI-Prism® 3100 (Applied Biosystems) at the 
HIV Unit of the National Institute for Communicable Diseases (NICD) using the 
standard cycle sequencing programme recommended for the BigDye® system. The 
primers used for the amplification of the product were used in the sequencing 
reaction. Each amplicon underwent two sequencing reactions, one with the forward 
primer to produce the forward sequence and one with the reverse primer to produce 
the reverse sequence.  
2.2.1.6 Bioinformatics 
 
For all samples, a forward and reverse sequencing reaction was performed and as 
such, each sample had two sequencing reactions per exon. At the terminal ends of 
each sequencing reactions, the data is often not useful as the signal is too weak and 
noisy to obtain the strong, clear peaks required for sequence determination, especially 
when the sequences are required for the determination of polymorphisms. 
Assembling the forward and reverse sequences allows the creation of a consensus 
sequence for the area of interest. Creating a consensus is important as it allows for 
data to be obtained for the entire area of interest. By aligning the forward and reverse 
sequences, the terminal ends of the reaction, which often have unreadable data can be 
supplemented by the complementary sequence. Sequences were assembled using 
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Sequencher Version 4.5 for Windows. The Basic Local Alignment search tool 
BLAST (www.ncbi.nlm.nih.gov/BLAST) was used to determine whether the 
sequences aligned significantly with any other sequences besides the target 
sequences. DNA alignments and translations, as well as Protein alignments were 
performed using DNAman version 4.03 and ClustalW (Thompson et al, 1994). SNPs 
were verified by comparison to SNPs recorded at dbSNP (Sherry et al, 2001), 
Ensembl (Hubbard et al, 2007), the UCSC genome browser (Kent et al, 2002), SNPer 
(Riva and Kohane, 2004) and the Japanese SNP database jSNP (Hirakawa et al, 
2002)  Secondary structure predictions were done using the PsiPred secondary 
structure prediction server (Bryson et al, 2005).All URLs are provided in the 
appendix  
 
2.2.2 HETEROLOGOUS EXPRESSION AND INTERACTION STUDIES 
2.2.2.1 cDNA synthesis  
 Reverse Transcriptase PCR was performed using the Access RT-PCR system 
(Promega) with the reaction mix and conditions described in Table 2  
Table 2:Reverse Transcription reaction mix  
Reagent Final concentration 
AMV/Tfl 5X reaction buffer 1X 
dNTP mix (10mM each dNTP) 0.2mM 
Upstream Primer (PGRP-S forward) 1µM 
Downstream Primer (PGRP-S reverse) 1µM 
25mM MgSO4 1mM 
AMV reverse transcriptase (5u/µl) 0.1u/µl 
Tfl DNA polymerase (5u/µl) 0.1u/µl 
RNA sample 5µg 
Nuclease free water To a final volume of 50µl 
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The cycling conditions were as follows: 1 cycle of 48oC for 45 minutes, 1 cycle of 
94oC for 2 minutes, and thirty cycles of 94oC for 30 seconds, 57oC for sixty seconds 
and 57oC for 68oC for 2 minutes. A final extension cycle at 68oC was performed for 2 
minutes.  
 
2.2.2.2 HETEROLOGOUS EXPRESSION OF PGRP-S 
2.2.2.2.1 Preparation of Competent cells  
An overnight E. coli BL21 (DE3) or E. coli XL1-Blue culture was diluted (1:20) into 
LB broth   containing no antibiotics. Diluted cultures were then grown at 37 ˚C until 
the absorbance at 600 nm reached 0.3-0.6 units (early log phase). The cells were 
harvested by centrifugation at 4 500 x g for 15 minutes at 4ºC in sterile centrifuge 
tubes. The cells were kept on ice at all times for the duration of the preparation.  The 
cells were then resuspended in ice-cold 0.1 M MgCl2 and left on ice for a further 20 
minutes. The cells were then collected as above by centrifugation for 15 minutes and 
resuspended in ice-cold 0.1M CaCl2 and left for 1 hour.  Cells were collected and 
gently resuspended in ice-cold 0.1M CaCl2.  The cells were stored in 1 volume of ice-
cold sterile glycerol (30 %) at –70 ˚C.    
 
2.2.2.2.2 Preparation of pGEM-T/PGRPS vector 
 
Ligation into pGEM-T easy vector (Promega) was according to the manufacturer’s 
instructions.  The ligation cocktail consisted of 2 µg of the PGRP-S cDNA fragment, 
50 ng plasmid and 3.5 units of T4 DNA ligase.  The T4 DNA ligase was at ratio of 
1unit/µg of DNA.  The reactions were incubated overnight at 4oC. pGEM-T easy 
plasmid without an insert was used as a ligation control.  
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2.2.2.2.3 Preparation of pET41/PGRPS vector  
 
pET41 (a) was linearized by restriction digestion with EcoR1 and XhoI. Calf 
intestinal phosphatase (CIP) was used to treat linear plasmid molecules at a ratio of 
0.5 units per µg DNA in a manufacturer recommended buffer. The reaction was 
incubated at 37oC for 30 minutes. The tube was heated at 65oC for 15 minutes and 
was followed by phenol chloroform isoamyl (25:24:1) extraction to stop the reaction 
as outlined in section 2.2.2.5.  The linearization of the plasmid was confirmed by 
agarose gel electrophoresis 
 
2.2.2.2.4 Transformation of competent cells 
 
An aliquot of competent cells was transferred into a sterile microcentrifuge tube 
containing 100 ng of plasmid on ice. The tube was flicked gently to mix the contents 
and placed on ice for 20 minutes. The cells were heat shocked at 42˚C for 45 seconds 
and immediately returned on ice for a further 2 minutes. Luria Bertani broth was 
added to the cells and incubated for 2 hours at 37 ˚C with shaking. Cells were plated 
onto LB agar plate containing appropriate antibiotics; ampicillin (100µg/ml) for XL1-
Blue cells and kanamycin for BL21 (DE3)(pLysS) cells. pGEM-T easy colonies were 
selected on the basis of blue/white screening, which was confirmed by restriction 
digestion of plasmids from white  colonies to confirm the presence of the insert. 
Similarly, plasmids from colonies of pET-41 transformed E. coli BL21 cells were 
tested for the presence of insert with restriction digestion.  
 
2.2.2.2.5 Small-scale plasmid DNA preparation of pGEMT/PGRPS; pET-
41/PGRP-S 
 
A sample of an overnight  culture of E. coli XL1-Blue transformed with pGEM-T 
Easy/PGRPS or BL21 (DE3) (pLysS) transformed with pET-41/PGRP-S was 
centrifuged at 16 000 x g for 1 minute, and the cell pellet resuspended in 100 µl of 
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Alkaline lysis solution I.  Solution II was then added and the suspension incubated on 
ice. After 2 minutes, 150 µl of solution III was added and the suspension was mixed 
gently by inversion and incubated on ice for a further 5 minutes. The sample was 
extracted twice, first with phenol: chloroform: isoamyl (25:24:1) followed by 
chloroform.    The aqueous layer was transferred into a fresh microcentrifuge tube, 
followed by DNA precipitation with ethanol acetate.  The mixture was incubated for 
30 minutes at –70oC.  The DNA was pelleted by centrifugation at 12, 000xg for 10 
minutes, washed with 70% ethanol and air dried at room temperature for 10 minutes.  
DNA was reconstituted with appropriate volume of sterile distilled water.  
 
2.2.2.2.6 Overexpression and Purification of the GST-tagged fusion protein  
 
 The optimal inducer concentration and induction time was determined by an 
induction study to determine the optimal conditions for protein induction.  
A single colony of E. coli BL21 (DE3) pLysS transformed with the PGRP-S/pET-41 
construct was inoculated into LB broth and grown for 16 hours. This culture was 
diluted 1: 25 and grown to an optical density at 600nm of 0.6 (mid-log phase). The 
culture was induced with 2mM isopropyl β-D-1-thiogalactopyranoside (IPTG).  The 
cells were allowed to grow for 16 hours before being harvested by centrifugation at 
5000xg for 10 minutes. The cell pellet was resuspended in 1M Cell lysis buffer 
containing 1mM aprotonin, leupeptin, phenyl methyl sulfonyl fluoride (PMSF) and 
EDTA. The cell suspension was sonicated for 30 seconds and insoluble protein was 
removed by centrifugation at 12 000rpm for 20 minutes. The supernatant was retained 
for purification of the Glutathione S-transferase (GST)-tagged protein.  
 
Soluble protein extract isolated from E. coli BL21 (DE3) pLysS twice with 10-
column volumes GST wash/bind buffer.  The fusion protein was eluted from the 
matrix with 3x volumes of GST elution buffer. All collected fractions were 
electrophoresed on a 12% polyacrylamide gel according to the method of Laemmli 
(1970). The analysis of the gels were performed as described in section 2.2.2.2.8   
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2.2.2.2.7 Interaction Studies using Pull-Down Assay  
 
The ability of the fusion protein to interact with soluble protein from Drosophila 
melanogaster was to be determined. The total fly protein fraction protein was 
prepared by homogenising 15 flies in 1.5ml of radioimmunoprecipation assay (RIPA) 
cell lysis buffer containing 1mM aproptinin, leupeptin, PMSF and EDTA. The 
homogenate was centrifuged for 30 minutes at 13 000xg and the supernatant retained 
for the interaction study. The success of the extraction was determined by SDS-
PAGE analysis as described in section 2.2.2.2.8.  
 
An overnight culture of M. luteus was harvested by centrifugation at 5000xg for 10 
minutes. The pelleted cells were resuspended in 1M Cell Lysis buffer, and sonicated 
for 30 seconds. The insoluble protein was removed by centrifugation at 13 000xg for 
10 minutes.  The insoluble fraction containing the cell wall component and 
subsequently the peptidoglycan fraction was resuspended in phosphate buffered 
saline containing 1mM aproptinin, leupeptin, PMSF and EDTA and sonicated for 10 
seconds. This was retained as a positive control for interaction with PGRP-S, as 
peptidoglycan is the natural ligand for PGRP.  The soluble fraction was retained as 
negative control, as no known ligands for PGRPS should be found in this fraction.  
 
E. coli BL21 (DE3) pLysS cells transformed with pET-41a without any insert were 
prepared as described in section 2.2.2.4. These transformed cells were then induced to 
overexpress as described in section 2.2.2.6 in this way GST was purified. This was 
used as a negative control. 
 
PGRP-S/GST fusion protein was immobilised onto four separate GST matrix 
columns. Soluble fly protein was added to one GST matrix and allowed to interact 
with the immobilised fusion protein for 18 hours at 4oC. Similarly, insoluble bacterial 
protein, soluble bacterial protein and pure GST were allowed to interact with the 
fusion protein. The column was washed with 8 volumes of GST-wash solution from 
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the GST Bind Kit® (Novagen). Protein complexes were eluted with 3 volumes of 
GST Elution solution from the GST bind kit® (Novagen).  
 
 
2.2.2.2.8 SDS PAGE analysis  
 
The sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) 
method described by Laemmli (1970) was used to separate protein for analysis. SDS-
PAGE makers (Fermentas) were used to determine protein size. The gel was 
electrophoresed at 120V for 120 minutes, Stained in coomassie brilliant blue G 
(Sigma) staining solution and destained overnight. The electrophoretograms were 
visualised using a GS-800 calibrated densitometer (Biorad) 
 
2.2.2.2.9 Radial diffusion Assays 
 
An overnight culture of bacteria (S. aureus, E. coli, M. luteus) was inoculated into LB 
Broth and grown with shaking at 37oC for 18 hours. Midlogarithmic phase organisms 
were obtained by re-inoculating the overnight culture in a 50 000X dilution of fresh 
LB broth and incubated at 37oC for 3 hours. The bacteria were harvested by 
centrifugation at 900xg at 4oC for 10 minutes. The cells were washed with cold 
10mM Sodium phosphate buffer pH 7.4. The cells were resuspended in three 
different types of 10mM Sodium phosphate buffer pH 7.4;  Sodium phosphate 
without a salt supplement, phosphate buffer with 5mM CaCl2 and phosphate buffer 
with 10µM ZnCl2. The optical density was measured at 620nm and used to calculate 
a volume of cells to use in order to obtain a volume containing 4 x 106 colony 
forming units and this was added to an underlay agar of LB broth, 1% agarose and 
0.02% Tween 20. This mixture was used to prepare a pour plate in which holes were 
punched and 1µg/µl fusion protein was added. As a positive control 12µg/ml 
tetracycline was used and as a negative control the buffer in which the fusion protein 
was suspended. This was incubated at 37oC for three hours. An overlay agar layer 
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consisting of LB broth and 1% agarose was poured over this preparation after the 
incubation and the plates were incubated for 18 hours. The clearings were visualised 
after staining with Coomasie brilliant blue R-250 for 18 hours. The plates were 
destained with an aqueous solution of 10% acetic acid and 2% dimethylsulphoxide 
for ten minutes.  
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CHAPTER THREE 
 
RESULTS 
 
3.1 Genetic Analysis 
3.1.1 Population distribution of experimental samples 
Single nucleotide polymorphisms in the PGRP domain of PGRPs of Drosophila, 
particularly the short forms, can result in the immunocompromise of the mutant flies 
(Lazzaro et al, 2004). The aim of the genetic analysis portion of this study was to 
determine whether increased levels of SNPs could be associated with the HIV and 
HIV/TB positive population.  The HIV positive population constitutes a pool of 
immunocompromised humans to screen. Tuberculosis is a disease commonly 
associated with HIV positive patients. Mycobacterium tuberculosis is an acid fast 
Gram positive bacterium (Madigan et al, 1997) and  should be recognised by PGRP-
S, it may hint at dysfunctional PGRPs. 
 
The establishment of databases detailing variation within the human genome has been 
vitally important since the release of the first draft genome. The establishment of a 
“reference genome” is a difficult and contentious task. For example, in the sequence 
of only one individual, James Watson, two million polymorphisms, most of which 
have already been noted (Egholm, 2007). It is because of the variant nature of 
genomes that several variation databases exist. The largest and most referenced is 
dbSNP at NCBI (Sherry et al, 2001). This database has 9 million variations noted to 
date (Egholm, 2007). Other databases include Ensembl (Hubbard et al, 2007), the 
Japanese SNP database jSNP (Hirakawa et al, 2002), the UCSC genome browser 
(Kent et al, 2002), and SNPer (Riva and Koane, 2004). Many of these databases 
reference dbSNP. 
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Sequences for these populations commonly come from either cell lines, 
predominantly sourced from Caucasians, or from several specific population groups. 
These include the Han Chinese from Beijing (HCB), Japanese from Tokyo (JPT), 
Utah residents with West European ancestry (CEU), and Yoruba from Ibadan in 
Nigeria (YRI) (Hubbard et al, 2007). The YRI population and several sequenced 
African American individuals represent the data from Africa. The genetic information 
from sub-Saharan Africa is therefore grossly underrepresented. This study therefore 
presents the first genetic survey of population variance of the PGRP-S gene in 
individuals from the region. The study groups were divided into groups of healthy 
controls, HIV patients on antiretroviral treatment (HIV) group, and HIV patients on 
antiretroviral treatment and Tuberculosis medication (HIV/TB). The population 
distribution of these three groups are represented in Table 3. The populations are 
based on language groups, as genetic homogeneity cannot be ensured. As no South 
African populations were isolated, and intermarriage between different language 
groups occurred. 
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Table 3: Population distribution of experimental groups 
  
Sample Group Population  Number of Inviduals 
Healthy Controls Zulu  7 
 Sotho 3 
 Xhosa 4 
 Other 2 
HIV positive Zulu  6 
 Sotho 6 
 Tswana 2 
 Tsonga 1 
 Xhosa 1 
 Other 1 
HIV/TB positive Zulu  7 
 Sotho 5 
 Ndebele 1 
 Tsonga 2 
 Venda 1 
 Other 1 
 
3.1.2 Amplification of coding regions 
This study is a pilot study on variation in the Southern African Sub-Saharan African 
population and as such did not consist of a large survey group. The Yorubi of Nigeria 
is only other group in Africa examined for variation in this gene.  Furthermore, only 
the coding regions were amplified because the study by Lazzaro showed the 
significant variation was variation within the regions coding for the PGRP domain 
(Lazzaro et al, 2004).  Variations in the introns were therefore not considered. The 
introns were only included in the study to a small extent as the forward primer was 
designed to bind upstream of the 5’ untranslated region and the reverse downstream 
of the end of the 3’ region of each exon. In that way the full length of the coding 
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region would be amplified and the amount of ambiguous sequencing data at the 
beginning and end of the sequencing reaction would be minimised. 
 
As Exon 2 and 3 were separated by 60 base pairs, both regions were amplified as a 
single product, referred to as Exon 2. The amplification of Exon 1 of patients 1-14 is 
depicted in figure 7. The amplification of Exon 2 of patients 15 to 19 is depicted in 
figure 4. Amplicons of both Exon 1 and 2 were obtained for 48 patients. The 
remaining two patients’ gene failed to amplify.  
 
 
 
Figure 4: Routine Amplification of PGRP-S.  Exon 1 in Block A and Exon 2 in 
Block B.  A 1% electrophoretogram demonstrating the 400 base pair (bp) Exon 1 
amplicon and 600bp Exon 2 amplicon.   These amplicons were subsequently used in 
sequencing  reactions.  Lanes 2-15 of block A represent samples of the first exons 
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from Patients 1 to 14 respectively. A negative control using Drosophila DNA as a 
template is represented in lane 16. Lanes 2-4  of Block B represent the second exon of 
Patients 15 to 19.  A negative control using Drosophila DNA as template is 
represented in lane 7. In both diagrams the Fermentas 100bp plus DNA ladder is used 
as a molecular weight marker.  
 
 
3.1.3 Sequencing of PGRP-S 
 
The amplicons of the patients in the study were electrophoresed and gel purified 
before automated DNA sequencing. The BigDye® terminator system was used for 
the direct sequencing of the amplicons, as detailed in section 2.2.1.5. To ensure that 
mutations were not introduced by exposure of the agarose gel to ultraviolet light, the 
intercalating agent Ethidium bromide was replaced with SyBr Gold (Invitrogen), 
which required blue light and therefore would not induce mutations.  
 
3.1.3.1 Confirmation of sequencing data 
 
Two assemblies exist for the genomic sequence of Chromosome 19. NT 011109.15 is 
referred to as the reference sequence and NW 927217.1 as the alternate assembly. 
The mRNA transcript, AF076483, originally described by 2001, is referred to as the 
reference mRNA sequence (Liu et al, 2001). In this project, all primers were designed 
using this sequence. 
 
To determine whether the obtained sequences were PGRP-S, the Basic Local 
Alignment Sequence Tool (BLAST) was used to determine whether the sequences 
obtained aligned with the reference sequence at the NCBI database. Aligning the 
sequences obtained resulted in two hits in the genome, both on chromosome 19. All 
the sequences matched the sequence for PGRP-S on both the reference and alternate 
assembly of the chromosome only, confirming that the sequences obtained were 
PGRP-S.  
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3.1.3.2 Determination of Single Nucleotide Polymorphisms 
 
In this study, only the coding regions were examined as the primary aim was to 
determine whether novel protein variants of PGRP-S existed.  As described in section 
2.2.1.3, non-coding regions of the gene were included in the amplification and 
subsequent sequencing of the gene. This was to ensure that the area of interest would 
be fall well into the sequencing reaction and thus avoiding the poor quality sequence 
data associated with the terminal ends of the reaction.  To obtain a full sequence of 
transcript from the sequences obtained for each sample both Exon 1 and 2 for each 
reactions were aligned to the mRNA. In this manner, all non-coding regions could be 
trimmed off and as a result, only the sequence for the transcript would remain.  
 
Table 4: Summary of known non-coding variation in the PGRP-S gene from the 
dBSNP, Ensembl, HapMap, jSNP, SNPer and UCSC genome browser databases 
SNPid reference contig 
position 
SNP Ancestral 
allele 
 
function 
 
population frequency 
data 
 
rs61513108 8793133 A/G unknown intron none 
rs61497458 18792085 A/G unknown intron none 
rs61403305 18794085 G/T unknown intron none 
rs60612918 18792689 C/T unknown intron none 
rs58866037 18791600..18791601 -/TT unknown intron none 
rs58829899 18793324 A/G unknown intron none 
rs58401596 18788946 C/G unknown intron none 
rs57714530 18792514 A/T unknown intron none 
rs11477830 18791591 -/T unknown intron none 
rs8106183 18792825 A/G A intron G allele freq 0.0034 in YRI 
rs3786822 18793324 A/G G intron none 
rs2302788 18789744 A/G unknown intron HAP map allele 
rs2072561 18794085 G/T T intron HAP map allele 
rs2041993 18793185 A/G G intron HAP map allele 
rs2041992 18792689 C/T C intron HAP map allele 
rs2041991 18792514 A/T A intron Asian/Caucasian data 
rs12461346 18789290 A/G unknown intron none 
rs11669048 18788946 C/G unknown intron none 
rs11083793 18789163 A/T unknown intron none 
rs57027496 18794866 A/G unknown 5′ near gene none 
rs55645419 18794693 A/C unknown 5′ near gene none 
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SNPid reference contig 
position 
SNP Ancestral 
allele 
 
function 
 
population frequency 
data 
 
rs11880830 18794626 C/T C 5' near gene 
No T allele found in 
samples of CEU, HCB, 
JPT, YRI 
rs7245826 18794744 A/G unknown 5' near gene none 
rs7245473 18794671 C/T unknown 5' near gene none 
rs2341638 18794777 C/T unknown 5' near gene none 
rs2072563 18794866 A/G unknown 5' near gene HAP map allele 
rs59433803 18794671 C/T unknown 5' near gene none 
rs61742389 18788724 C/G unknown 3' near gene none 
rs35952458 18790254 -/C unknown 3' near gene none 
rs2072562 18794516 G/T G 5'UTR none 
rs60974605 18794516 G/T unknown mRNA (26) none 
rs1054882 18790024 C/T unknown 3' untranslated none 
rs1054881 18789994 C/T unknown 3' untranslated CEPH 
The cells highlighted in yellow represent a duplication in the dbSNP database, where  
the same polymorphism was submitted twice. In the above table, as well as the table 
below, previously recorded polymorphisms found in this study are highlighted in 
green.  
 
Table 5: Summary of known variation within the coding region of PGRP-S from the 
dBSNP, Ensembl, HapMap, jSNP, SNPer and UCSC genome browser databases 
SNPid reference contig 
position 
SNP Ancestral 
allele 
 
function 
 
population frequency 
data 
 
rs59269540 18789565 C/T unknown synonmous none 
rs34478490 18794265^18794266 -/CG unknown mRNA (227)   
rs34180629 18794397 A/C unknown 
missense, 
mRNA(145)G-
V 
AA population: C allele 
0.026 
rs28722714 18794222 A/G G 
synonmous 
D(92)D 
AA population: A allele 
0.038 
rs13343537 18791051 G/T G 
missense, 
mRNA(404)H-
Q 
No T allele found in 
samples of CEU, HCB, 
JPT, YRI 
rs34323192 18789815 -/C C Frameshift none 
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Figure 5: Truncated Clustal W multiple alignment of samples highlighting the 
variations observed by direct sequencing. 
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In the figure above, PGRPS represents the reference mRNA sequence, and consensus 
transcript sequences assembled as described in section 3.1.3.2. The number prefixing 
the term refers to sample number 
 
Every sequenced sample differed from the mRNA transcript at position 80. The allele 
in the transcript is a T while all the genomic sequences were homozygous for a C at 
that position. The substitution does not change the amino acid coded for, as both 
forms of the codon in question, CCC and CCT codes for a proline residue. 
Nonetheless, it is striking that all the genomic sequences differ from the mRNA 
transcript. It is not recorded as a DNA polymorphism and all PGRP-S reference 
genomic  sequences examined (GenBank, the UCSC genome browser and Ensembl) 
have a C at that particular position. In mRNA sequences from all of the above 
databases, a T allele is found in this position.  
 
Further examination of alignments of the sequenced samples showed that the 
individuals sequenced did not show significant variation from the standard mRNA 
sequence. Only 5 variations were found with 2 polymorphisms previously observed 
and 3being potentially novel. The polymorphisms are highlighted in the Clustal W 
alignment presented in Figure 5. The genotypes of all the polymorphisms were 
determined by direct examination of the chromatograms, are summarized in table 6). 
 
The first polymorphism observed corresponds to mRNA position 26. This has been 
previously observed, and is referred to as rs2072562. The polymorphism lies in the 5’ 
untranslated region and therefore has no bearing on the gene sequence of the gene 
product. In this study group the C-allele occurs with a higher frequency (0.53) than 
the A-allele (0.47). NCBI states that the C-allele is the ancestral allele. At present 
there is no recorded frequency data for this polymorphism at either NCBI or 
Ensembl.   
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 Another previously described polymorphism, a C/T substation at mRNA position 
320 called rs28722714, occurs in 6 patients, 3 HIV/TB patients, 2 HIV patients and 1 
healthy control. All six these patients are heterozygous for the polymorphism as 
observed in figure 6.  
 
Figure 6: Partial sequence analysis of Exon 1 of Patient 27. Patient 27 is has a 
polymorphic site at position 320 of the mRNA. The patient is heterozygous for C and 
a T allele at this position.  
 
Both codons encode Aspartic acid. This previously noted polymorphism is observed 
in 6 patients, 3 HIV/TB patients, 2 HIV patients and 1 control. The calculated 
frequency of heterozygosity listed at NCBI is 0.074 for the African American 
population, and therefore much lower than the frequency of 0.3 found in this sample 
population group. However, this is likely to be a function of the small sample size. 
No TT homozygotes were observed in the sample group and this is echoed by NCBI, 
which also does not record any TT homozygotes in the population sampled.  
 
A variation at position 651 was observed in sample 12. This was not observed in any 
other patients and examination of the chromatogram showed that this C/T (Y) 
ambiguity may be more a function of poor sequencing and can only be confirmed by 
further rounds of sequencing.  
 
Sample 15 contained an A-allele at position 110 instead of a G.  Examination of the 
chromatogram showed that the polymorphism (representing a synonymous 
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glutamine-glutamine substitution). Although not as neatly demonstrated as the 
polymorphism at 320, the R ambiguity does occur four times. Further samples and 
more sequencing can determine whether this polymorphism which has not been 
reported at NCBI, Ensembl, JSNP, SNPer or the UCSC genome browser is indeed a 
novel polymorphism.  
 
PGRP-S contains what is described by Ensembl as residue splice junctions. Two 
residues, asparagine 75 (96 on the immature peptide) and aspartic acid 116 (136 on 
immature peptide) are coded for by codons which span Exon 1 and 2 and 2 and 3 
respectively. The CAA codon for asparagines falls at the end of Exon 1 (CA) and the 
beginning of Exon 2 (A). A polymorphism is observed in sample 6 at mRNA position 
312 where the patient is homozygous for G and not the middle A of the codon. This 
polymorphism is unobserved in any other sample and is not recorded at any of the 
databases used to confirm polymorphisms. If confirmed by further rounds of 
sequencing and an altered PCR strategy to be discussed later, not only does this 
represent a potentially novel polymorphism, but also a variation leading to an amino 
acid change that is previously unreported.  
 
Table 6: Frequency polymorphic genotypes distributed among control, HIV positive 
and HIV/TB positive groups. 
Genotype 
mRNA 
Position Exon n Frequency 
CC 27 1 6 0.3 
CA 27 1 13 0.65 
AA 27 1 1 0.05 
GG 110 1 16 0.8 
GA 110 1 4 0.2 
CC 320 1 12 0.6 
CT 320 1 8 0.4 
CC 651 3 18 0.9 
CT 651 3 2 0.1 
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Of the polymorphisms examined, only rs2072562 had all both homozygotes (CC/AA) 
and therefore this was the only sample that could be examined for Hardy-Weinberg 
equilibrium. 
 
As the frequency for the C-allele is 25/40 and the A-allele is 15/40, the Hardy-
Weinberg equation would look as follows: 
 
p2+2(pq)+q2 = 1 
(25/40)2 +2(25/40)(15/40) + (15/40)2 
= (0.625)2 + 2(0.625)(0.375) + (0.375)2 
0.390625+ 0.46875+0.140625= 1. 
Therefore, for this SNP, the alleles are in Hardy-Weinberg equilibrium. To test this, a 
Chi-squared test was performed, where the null hypothesis is that the alleles are in 
equilibrium. 
 
χ2 = ∑(observed-expected)2/expected 
= [(6-7.8125) 2 + (13-9.3750) 2 + (1-2.8125) 2] 
      7.8125               9.3750              2.8125 
= 0.421/7.8125 + 1.41/9.3750 + 0.421/2.8125 
= 2.25. 
As the χ2 test has one degree of freedom (df) and a 5% confidence interval with 1df 
is 3.84, the alleles are in equilibrium. 
 
3.2 Bioinformatics analysis  
 
3.2.1 Protein alignment 
 
The sequencing results demonstrated both previously reported and potentially novel 
polymorphisms. The discovery of previously noted polymorphisms  give validity to 
the quality of the sequencing, and indicate that a further sampling may confirm the 
existence of the novel polymorphisms found. To determine whether the 
polymorphisms resulted in amino acid changes or frameshift mutations, the 
sequences for the coding regions were translated.  
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Patient 6 was the only patient with a non synonymous change as shown in Figure 24.  
To date, only three polymorphisms have been reported in the open reading frame of 
PGRP-S. Of those three reported polymorphisms (rs34180629, rs13343537 and 
rs28722714), only two were missense mutations, and the remaining SNP a 
synonymous one. As only these polymorphisms have been reported since the 
discovery of the gene, a new protein variant is therefore an interesting new avenue for 
exploration. Although the existence of variants of the protein has been reported, there 
is currently no published literature on the effect of variant amino acid residues on the 
structure and functionality, particularly with respect to the ability of the protein to 
bind peptidoglycan. Thus, as no body of literature exists on the subject, it is therefore 
very important to examine the nature of the variant protein to determine how 
differently it would behave compared to the wild type PGRP-S.  
Figure 7: Multiple alignment of the translated mRNA sequences of the HIV/TB 
positive group with PGRP-S standard amino acid sequence 
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A non-synonymous change is found at amino acid position 75 of the mature peptide 
of patient 6. Asparagine is substituted with Serine. This is a conserved amino acid 
change in terms of charge, as both amino acids are neutral and polar, but the 
bulkiness of the side chain has been greatly reduced. Patient 6 is the only patient with 
a non-synonymous polymorphism.  
 
3.2.2 Secondary structure predictions  
 
3.2.2.1 Secondary structure predictions of PGRP-S and variant proteins  
 
The variant protein of Patient 6 differs by one amino acid only. However, the amino 
acid is located in a secondary structural motif (a strand). The change could potentially 
also affect the protein’s secondary structure. Secondary structure prediction was 
performed on the mutant protein using the PsiPred secondary structure prediction tool 
(Bryson et al, 2005; Jones et al, 1995). As the crystal structure for Wild-type PGRP-S 
has been elucidated, a secondary structure prediction on the wild type amino acid 
sequence has a twofold purpose. It can serve as a visual reference to compare the 
mutant secondary structures too and can serve as a form of quality control on the 
accuracy of the secondary structure prediction tool.   
 
Figure 8 shows a comparison of the secondary structure prediction for the wild type 
PGRP-S protein, as well as a structure prediction for the variant protein of patient 6. 
According to the prediction, the single amino acid change results in large changes in 
the secondary strucure of the protein. The accuracy and validity of the prediction will 
be discussed further and in greater detail in section 4.5.  
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Figure 8: Secondary structure predictions of mutant samples from Patient 6(A) and 
Wild type PGRP-S (B) using the PsiPred Secondary structure prediction tool.  
 
In the above representation the helices are represented by green barrels and strands by 
yellow area. A comparison of the predicted structure with the crystal structure 
deposited at the Protein Databank (1YCK) revealed that the prediction was not highly 
accurate in predicting the amount of secondary structural motifs. Of the structures 
correctly predicted, the lengths of the motifs were at most off target by two residues. 
The incorrect residues were always predicted with low confidence. The secondary 
structure prediction of Patient 6 (Structure A) differs from the prediction given for the 
wild type protein. This could possible be due to the fact that the amino acid change is 
at the beginning of a strand and could therefore have an effect on the folding 
dynamics. The accuracy of the prediction can be called in to question as it predicts 
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that a structure found in all PGRPs is missing in the mutant. The structure in question 
is demonstrated in Figure 9.  
 
3.2.3.2 Conservation of structural motifs across PGRPs. 
 
A secondary structure feature reported to be conserved in all PGRPs, both vertebrate 
and invertebrate, where the structure of the molecule has been elucidated is a 
conserved helix structure, preceded by a strand. Notably, while the helical structure is 
present in sample 6, the strand is missing. Both these structures are preserved in 
PGRPs across several species and in all in forms of the protein (short, intermediate or 
long), and therefore the absence of this motif is remarkable. Figure 10 highlights the 
conservation of this particular structural motif across species.  
 
All secondary structure predictions performed for short PGRPs have this motif, and 
therefore the missing motif in sample 6 is noteworthy. This could either be a 
significant change due to the position of the amino acid in its particular structural 
motif, or a reflection of the nature of secondary structure prediction tools being 
unreliable.  This will be discussed later in greater detail.  
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Figure 9: PsiPred predictions highlighting a conserved motif found in PGRP-S found 
in different organisms.  
 
Block A represents PGRPSB2 from Drosophila melanogaster; Block B represents 
PGRP SC2, also from Drosophila. Block C represents PGRP SD from Drosophila. 
Block D represents the mouse cytokine Tag 7. Block E represents PGRP-S in 
humans. Block F represents sample 6. All secondary structure predictions done of 
short PGRPs have this motif, and therefore the missing motif in Patient 6 is 
noteworthy. This could either be a significant change, or a reflection of the nature of 
secondary structure prediction tools being unreliable. This could be confirmed not 
only by Circular dichroism spectroscopy or by in vivo studies to determine whether 
the amino acid substitution and the subsequent potential change results in a 
phenotype alteration.  
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3.2.3 Tertiary structure analysis 
An amino acid change would not only potentially affect the secondary structure of the 
protein, but also the intramolecular contacts of the tertiary structure. As the tertiary 
structure of PGRP-S is recorded at the Protein Data Bank as 1YCK, the Swiss PDB 
viewer was used to mutate the wild type asparagine (N) to the serine residue of the 
mutant protein. The steric changes induced by change in residue are observed in 
Figure 10.  
 
When examining changes in amino acid residues, it is important to note the change in 
polarity, hydropathy and side chain constitution and bulkiness as all these factors will 
play a role in the secondary structure and consequently tertiary structure and function 
of the protein. Steric hindrance is of particular importance for protein interacting with 
a substrate, as the obstruction of the binding of the protein to the target will have an 
effect on the function of the protein. The location of the residue change is also 
therefore important. Changes in active sites or near residues that interact with 
substrates are particularly significant. The location of the variant residue in the 
protein of PGRP-S is therefore of interest. Currently, no crystal structures exist for 
peptidoglycan docked in PGRP-S. However, homology assisted docking of a PGRP-S 
analogue, muramyl tripeptide, was performed and used to determine which residues 
interact with peptidoglycan. These residues are refered to as “potential peptidoglycan 
binding residues”. One of these residues is tyrosine 74 (Guan et al, 2005). As the 
variant residue lies next to this significant amino acid, the changes resulting from the 
substitution may therefore have significant effects on the behaviour of the protein. 
This will be discussed in grater detail in section 4.5.  
.      
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Figure 10: Structural analysis of PGRP-S (1YCK) and Patient 6 using the Swiss 
PDB viewer.   
 
 
Blocks A and C represent the wild type protein, and blocks B and D the mutant 
protein. The residue mutated is represented in red and the neighbouring residue in 
yellow.  
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The Swiss PDB viewer can be used in the analysis of an elucidated protein structure 
deposited at the Protein Data Bank (PDB) (Guex, and Peitsch, 1997). The non-
synonymous residue, Asparagine75 is next to Tyrosine 74, a potential peptidoglycan-
contacting residue. The residue was mutated to the predicted Serine75 found in 
patient 6. The potential effect on interactions was examined. Block A is a view of the 
top of the wild type protein, and Block B is view of the mutant protein in the same 
orientation. The arrows indicate the proximity of the side chain of residue 75 with the 
phenol ring of the tyrosine molecule. The tyrosine molecule is a putative 
peptidoglycan contacting molecule, and therefore it’s proximity to the target molecule 
is crucial (Guan et al, 2005). In Block A and B, it can be observed that the side-chain 
of the serine is much closer to the phenol ring of tyrosine 74. When rotating the 
molecule to a different view, it is still evident that the variant side chain is closer to 
the phenol ring of tyrosine 74. As the peptidoglycan molecule interacts with tyrosine, 
the decreased intermolecular distance between the residue and its’ neighbouring 
amino acid may potentially interfere with interactions that residue may be involved 
in.  
 
From the above figure, it appears that the mutation induces a change in the 
intramolecular distance of the mutant residue and its’ neighbouring tyrosine residue. 
This can be confirmed by measuring the distance between the molecules using the 
atomic distance measurement function of the Swiss PDB viewer. The distances 
between the two molecules are depicted in Figure 11.  
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Figure 11: Measurement of distances between residues 74 and 75 of wild-type PGRP 
and the variant  protein of Patient 6.  
 
Tyrosine 74 is represented in yellow, residue 75 (asparagine in the wild type and 
serine in the mutant) is represented by in red. Phenylanlanine 76 is represented in 
green.  
 
From the measurements of the extremities of the side chains, it is clear that the 
distance between the residues are indeed decreased, with the furthest distance 
decreasing from 11.95Å to 10.79Å, From the orientation of the molecules, it is 
possible that there is also a change in the hydrogen bonding pattern of the residues, as 
some hydrogen onds may be created or lost with the substitution of the variant 
residue. The Swiss PDB viewer can also be used to predict the location of the 
hydrogen bonds between the residue. This prediction is demonstrated in figure 12.  
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Figure 12: Hydrogen bonds between residues 74 and 75 of PGRP-S.  
 
The orientation of the side chains in the wild type protein (Block A) differs to that of 
the mutant (Block B). As previously mentioned residues 74 and 75 are brought into 
closer proximity in the mutant protein. Although no steric clashes between the 
residues are predicted by the Swiss PDB programme, there is a change in the 
hydrogen bonding profile, indicated in the figure as a dashed green line. Although the 
hydrogen bonds that are present in the wild type protein are conserved (as indicated 
by the black arrows), the mutant protein has two additional hydrogen bonds with its 
neighbouring amino acids (indicated by red arrows).  
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3.3 Biochemical analysis 
 
3.3.1 Heterologous Expression of a PGRP-S/GST fusion protein 
 
As outlined in section 8 of chapter one, the biological functions of short PGRPs differ 
significantly between vertebrates and invertebrates. While the different types of 
PGRP-S’ in Drosophila initate signalling transduction cascades and have direct 
enzymatic activity, current literature suggests that human PGRP-S is solely an 
antimicrobial peptide. This is rather unusual as in other organisms, the protein has a 
host of functions.  In the rat sleep deprivation results in increased expression of 
PGRP-S in brain (Rehman et al, 2001). Recently it has been demonstated that the 
protein is induced by the transcription factor RelA in cases of cerebral ischemia in 
mice (Lang et al, 2008). Therefore the potential exists for PGRP-S to have other 
functions besides that of an antimicrobial protein. To be able to begin to understand 
what this role could possibly be, a clearer understanding of the protein-protein 
interactions of PGRP-S is required. For this reason, in vitro interaction studies of the 
protein were performed.  
 
PGRP-S was successfully cloned, overexpressed and purified from E. coli BL21 
cells. It was cloned from a leukocytes obtained from a fresh culture of blood from a 
healthy control. PGRP-S is usually cloned from bone marrow, and for activity studies 
usually expressed in Drosophila S2 cells as the protein is reported to be glycosylated.  
Using the protein without any posttranslational modifications would give an 
indication of the importance of the modifications. Figure 13 demonstrates the final 
elution steps of the GST affinity purification. 
 
 
 
 66 
 
 
Figure 13: Purification of heterologously expressed PGRP-S/GST fusion protein.   
The first five lanes show the proteins washed from the column. Lanes 6-8 show the 
three reduced glutathione elution steps with the purified protein isolated in the second 
elution. The absence of protein in column 8, the third elution step, indicates that all 
the purified, GST-tagged protein eluted in the second glutathione elution.  
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3.3.2 Interaction studies of PGRP-S 
 
Various reports have stated that the mouse homologue of PGRP-S, Tag7, forms a 
cytotoxic complex with Heat Shock Protein 70 (Sashchenko et al, 2005). It has also 
been reported that besides peptidoglycan, PGRPs can interact with 
lipopolysaccharides as well. The  aim of the pulldown assay was  to determine 
whether human PGRP-S could interact with protein components of Drosophila 
melanogaster.  Figures 14 and 15 shows an interaction study which aimed to 
determine which proteins PGRP-S was capable of binding or forming an interaction 
with 
 
Figure 14: Pull Down assay to determine whether crude Drosophila melanogaster 
protein interacts with PGRP-S.   
 
PGRP-S/GST fusion protein and GST were bound to a GST affinity matrix. 
Drosophila protein was added to the column and allowed to interact overnight. Upon 
GSH-elution, only the fusion protein was observed in the elution step (Lane 2) and no 
unbound or fusion protein/interactor complexes were observed in the pre and post 
wasjing steps (Lanes 1 and 3, respectively) No interactions were found in the column 
with GST (Lanes 5-7, the prewash, elution and postwash steps respectively), the 
negative control. This was to demonstrate that had any interacting proteins had been 
found for the fusion protein, it was due to an interaction with PGRP and not its GST 
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fusion tag. The interacting capability of the recombinant protein was further 
examined with an extended set of control reactions depicted in figure 15.  
 
 
Figure 15: Pull Down Assay to determine whether human PGRP-S interacts with 
bacterial components.  
 
This electrophoretogram contains another set of controls. Lanes 1-4 contain a double 
negative control. GST bound to a GST affinity column was allowed to interact with 
bacterial components. Lanes 1 and 2 represent a GST interaction with Microccus 
luteus soluble and insoluble protein respectively. No interaction was found between 
GST and M. luteus components Lanes 3 and 4 represent a GST interaction with 
Escherichia coli soluble and insoluble protein respectively. As with M. luteus, GST 
did not interact with E. coli components. Lanes 5 and 6 represent a PGRPS/GST 
interaction with M. luteus soluble and insoluble protein respectively. Lane 7 and 8 
represent a PGRPS/GST interaction with E. coli soluble and insoluble protein 
respectively. The fusion protein interacted with bacterial components. These 
components would be very small protein components, as excluding the size of the 
fusion protein; the components in the complex would constitute 6 and 14kDa to the 
60 and 68kDa complexes respectively.  
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3.3.3 Activity studies of PGRP-S 
 
The interaction study demonstrated that the fusion protein is capable of binding 
bacterial components. As PGRP-S is antibacterial protein, a biochemical analysis 
would have to include antimicrobial assays. Radial diffusion assays were used to 
determine antibacterial activity as it is described as a method to obtain maximal 
sensitivity while using the minimal amount of protein (Lehrer et al, 1991). 
Furthermore, it eliminates the possibility of a false positive due to smearing of protein 
from an impregnated filter.  
   
 
Figure 16: Determination of antimicrobial activity of PGRP-S against Escherichia 
coli by Radial Diffusion assay.  
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E. coli was used as a representative Gram-negative bacterium, which PGRP-S does 
not preferentially bind to and is therefore not highly active against. No clearings were 
noted. To determine whether this was due to protein inactivity, the assay was 
supplemented with zinc chloride, as zinc is the divalent ion required for activity 
against Gram negative bacteria.  
 
 
 
Figure 17: Determination of antimicrobial activity of PGRP-S against Esherichia 
coli by Radial Diffusion assay supplemented with zinc chloride.  
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As with the unsupplemented assay, there was no noted antimicrobial activity. The 
fusion protein does not appear to be active against Gram negative bacteria. 
 
 
Figure 18: Determination of antimicrobial activity of PGRP-S against 
Staphylococcus aureus by Radial Diffusion assay.  
 
S. aureus was chosen as a representative Gram positive bacterium as PGRP-S is 
reported to have a bactericidal effect on this culture. As with E. coli, no clearings 
were noted, and similarly, the experiment was repeated with a zinc supplement, as 
this is the divalent ion required for activity against Gram positive bacteria.  
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Figure 19: Determination of antimicrobial activity of PGRP-S against 
Staphylococcus aureus by Radial Diffusion assay supplemented with Zinc chloride. 
As with the experiment testing the antimicrobial activity against E. coli with a 
calcium supplement, no clearings were noted. The fusion protein appears to have no 
antimicrobial activity.   
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Figure 20: Determination of antimicrobial activity of PGRP-S against 
Staphylococcus aureus by Radial Diffusion assay supplemented with calcium 
chloride.  
 
Calcium chloride can be used as an alternate ion source for activity against Gram 
positive bacteria. As with the experiment testing the antimicrobial activity against E. 
coli and S. aureus with a zinc supplement, no clearings were noted. The fusion 
protein appears to have no antimicrobial activity.   
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CHAPTER FOUR 
 
DISCUSSION 
 
4.1 Genetic substructure in sub-Saharan Africa 
 
The black South African population can be classified on a linguistic basis. The 
Sotho/Tswana group, the Nguni group and the Venda group. The Nguni group, 
comprising of Zulu, Xhosa and Tsonga speakers constitute 45.2% of first language 
home speakers. The Sotho group, comprised of Northern and Southern Sotho 
speakers as well as Tswana speakers constitutes 25.1% of first language home 
speakers (Lane et al, 2002). Populations from southern Africa are poorly represented 
in population sequencing studies. They may be similar to a group of African 
Americans designated the WAFR  (West African) described by Tian et al (2006).This 
group included the Bini, a group from the Edo state in Nigeria (Tian et al, 2006). 
Most black South Africans originated from a group that dispersed from the current 
Nigerian/Cameroonian border approximately 5000 years ago (Beleza et al, 2005). 
Since then, much differentiatiation has taken place, as geography, rather than 
language group, plays a more defining role in the African genetic landscape (Salas et 
al, 2002). The sub-Saharan African population is therefore a unique and relatively 
unexplored group as only the Yorubi of Nigeria has been examined for population 
variation.  
 
The pilot study conducted by this research had a sample size too small to make any 
firm conclusions about the distribution of variation in the population.  However, it 
does give direction for future study. Three of the four variant samples, Patients 12 
(Zulu), 15 (Sotho) and 27 (Zulu), are all Nguni speakers. Patient 6, however, is 
Venda. Vendas comprise a small portion of the South African population, and 
constitute only 2.2% of first language mother tongue speakers. Furthermore, Vendas 
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are the most genetically distinct of any of the groups examined. Phylogenetic analysis 
places them closer to Tsongas, an Nguni group, than any other population group 
based on autosomal and Y-chromosome data (Lane et al, 2002). They are considered 
to be one of the last population groups to migrate into Southern Africa. They settled 
in the Limpopo province in the North of South Africa and have had very little 
admixture with other population groups (Lombard et al, 2006).   Studies on variation 
in cytochrome P450 and Glutathione S-transferases (Dandara et al, 2002; Sommers et 
al, 1991) in the Venda population did not yield any variation from other African 
population. Vendas are predicted to be more susceptible to tuberculosis due to an 
increased frequency of the occurrence of variants in the vitamin D receptor. 37% of 
tuberculosis cases in the Limpopo province are in patients of Venda descent 
(Lombard et al, 2006).   It is therefore interesting to note that the most remarkable 
potential mutation takes place in a member of this population.  
 
4.2 Distribution of variation in the PGRP gene 
 
In the PGRP-S gene, a total of 39 Single Nucleotide Polymorphisms have been 
reported. Of those 39, 17 occurred upstream of the coding region, one in the 5’ 
untranslated region, 11 were intronic, and two were downstream of the coding region. 
Two frame shift mutations have also been noted (Hubbard et al, 2007). Of the 
polymorphisms in the coding region, four (rs13343537, rs28722714, rs34478490, 
rs34180629) have been reported, with one of the changes being a synonymous 
mutation at Aspartic acid 92 (Sherry et al, 2001). A recent study examined the 
sequence variability of bovine PGRP-S. The bovine protein is a 190 amino acid 
protein coded for by a 3 exon, 688 base pair transcript. The signal peptide, PGRP 
domain and zinc amide/N-acetylmuramoyl-L-alanine amidase acid (Ami_2) domain 
are conserved in humans, Mus musculus, Rattus norvergicus, Canis familiaris, Bos 
taurus and Bos indicus. The gene and protein structure is therefore conserved 
between cattle and humans. Only 3 SNPs were detected in the coding region, with 
two of them being non-synomous. The majority of variations found in bovine species 
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are transversions. Of the 6 SNPs observed in the coding regions of human PGRP-S, 
two insertions, two transitions and two transversions are noted. Overall, the published 
data points to the fact that, unlike Drosophila, variations leading to immunological 
consequences may not lie in the coding regions, but rather in the intronic regions. Of 
the variations within the coding regions, most of the variation was found in Exon 1, 
with one synonymous change in Exon 2 and none in Exon 3.  
 
4.3 Discovery of previously noted polymorphisms 
 
Polymorphism rs2072562 is a C to A substititution at mRNA position 26, reference 
contig position 18794516. This is a change in the 5’ untranslated region. This 
polymorphism, at present, has no frequency data. This study therefore represents the 
first genotype frequency data for this particular polymorphism. Of twenty patients, 
the CA heterozygous genotype occurs at a frequency of 0.75, the homozygous CC 
with a frequency of 0.15, and the homozygous AA genotype with a frequency of 0.1. 
The frequencies are not in Hardy Weinberg equilibrium. This is to be expected as the 
Hardy Weinberg equilibrium is based on an infinite or sufficiently large population. 
Twenty samples are therefore not representative. However, the frequency of the 
occurrence of the C-allele does appear to confirm the assertion by NCBI that the C-
allele is the ancestral allele as it occurs with an allele frequency of 0.53 compared to 
0.48 of the A-allele. The homozygous AA phenotype was only observed twice, in a 
HIV positive and an HIV/TB positive patient. This SNP is found to exist in Hardy-
Weinberg equilibrium.  
 
The previously reported polymorphism rs28722714 was detected in the patients 1, 4, 
6, 11, 15, 24, 27 and 29. This is a C to T substitution at mRNA position 320, 
reference contig position 18794222 and all the aforementioned patients are 
heterozygous for the polymorphism.  The C-allele is the ancestral allele. Again, in 
confirmation, the homozygous CC genotype is found occurring with a frequency of 
0.6. eight patients (frequency 0.4) were heterozygous for the CT genotype. Patient 27 
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is the first patient in which this polymorphism was observed. In all the heterozygous 
patients the allele was given an ambiguity code as the two bases could not be 
distinguished between each other. Both the C and T-alleles would result in the amino 
acid Aspartate. This is the second previously observed polymorphism found; 
validating the quality of the sequencing data and giving credibility to any potentially 
novel SNPs that may be found.  
 
4.4 A potentially novel synonymous polymorphism.   
 
A G to A polymorphism is observed at mRNA position 110. The first patient found to 
have this polymorphism was Patient 15, as this was the only patient with an A in 
position 110. Further investigation showed that the polymorphism was a 
heterozygous change. This genotype was observed 16 times, a frequency of 0.8. No 
homozygous AA genotypes were observed. Four GG homozygotes were observed, 
and this genotype was observed only in HIV or HIV/TB patients. The G allele is the 
reference allele from all databases. Furthermore this allele occurs with an allele 
frequency of 0.6. It is therefore possibly the ancestral allele. The change is a 
synonymous mutation (glutamine to glutamine). It is however, interesting to note that 
the polymorphism is at the beginning of the mature peptide. If a non-synonymous 
change had taken place at this position, it could potentially have implications on the 
processing and trafficking of the protein as it occurs at the point of splicing of the 
signal peptide and mature peptide.  
 
4.5 A potentially novel non-synonymous polymorphism 
 
Patient 6 has a homozygous A to C substitution at mRNA position 312.  It is a unique 
change, unobserved in both the sample population or previously noted in any 
database. This polymorphism is interesting for several reasons. Firstly, the existence 
of this polymorphism needs to be confirmed with more rounds of sequencing as the 
residue affected is a residue overlap splice site. This residue, as well as Aspartic acid 
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116 is coded for by a codon that overlaps two exons, with the resultant mutant reside 
falling on a junction of exon 1 and 2.  
 
Secondly, the polymorphism represents a potentially novel non-synonymous 
polymorphism. Only 1 synonymous and 2 non-synonymous polymorphisms have 
been reported on the NCBI, Ensembl, UCSC and SNPer databases. The 
polymorphism results in an Aspargine 75 to Serine substitution.  
 
None of the residues affected by the reported polymorphisms, or this potentially 
novel substitution, are cysteines involved in disulphide bonding. This would have 
been significant not only to the stability and tertiary structure of the protein, but 
would also be likely to affect the functionality of the protein, as the protein is 
reported to function as disulphide linked homodimer (Lu et al, 2006). 
 
No mutations are reported in any evolutionarily conserved residues, or residues 
involved in stabilizing reactions. Aspartate 71 and glycine 91 are predicted to form a 
bidentate salt bridge. These residues are unaffected. Tyrosine 85 forms a tight 
hydrophobic cluster with alanine 20 and 56 as well as tryptophan 18, a residue found 
in all insect and mammalian PGRPs (Guan et al, 2005). None of these residues are 
affected, 
 
The mutation in Patient 6 comes into play with peptidoglycan contacting residues. 
Histidine 40, threonine 41, tyrosine 62, histidine 63, tyrosine 74, histidine 96 and 99, 
asparagines 102 and glutamine 153 are predicted to be peptidoglycan contacting 
residues. Although these residues are not all located together in the primary sequence, 
in the tertiary structure of the protein they are found in and around the peptidoglycan 
binding cleft (Guan et al, 2005). Although the mutation in patient 6, asparagine 75 to 
serine, is not one of the predicted peptidoglycan contacting residues, serine 75 is next 
to tyrosine 74, which is predicted to be required for peptidoglycan contact. The 
mutation may therefore play a significant role in the protein’s functionality. 
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An asparagine to seine substitution is a conservative change in terms of electrostatics 
as both amino acids are uncharged polar amino acids. The asparagines residue is 
heavier than serine, 114.1D compared to 87.1D of serine. The pK value of the α 
carboxy terminal of the residues are similar, asparagines with a pK of 2.14 and seine 
2.19. The pK values of the α amino terminal of serine is higher (9.21) than that of 
asparagines (8.72) (Voet and Voet, 1995). A serine substitution also represents a 
change in hydrophobicity as it has a hydropathy of -0.8 compared to the -3.5 of 
asparagines (Kyte and Doolittle, 1982). The primary structural change is therefore a 
conservative in terms of charge and polarity, but results in a decrease in residue mass 
and a slightly increased hydrophobicity. 
 
A change in secondary structure is more difficult to predict. All secondary structure 
changes are all predicted by PsiPred (Bryson et al, 2005; Jones, 1999). The accuracy 
of this method is questionable.  The crystal structure of PGRP-S at the protein 
databank (1YCK) shows that structure has 5 helices and 7 strands. The PsiPred 
prediction predicts 7 helices and 5 strands. In terms of the prediction of the number of 
secondary structure, that is not a poor accuracy. However, the positions of the 
predicted secondary structures are grossly inaccurate. Of the predicted structures, 
only one helix is corresponds to the actual helix in that region.  
Of the seven strands, only two of the strands predicted by PsiPred are in the correct 
region. Not a single secondary structure position is perfectly predicted. One of the 
secondary structures that were predicted with a degree of accuracy is a 310 helix 
reported to be found in all PGRP structures (Guan et al, 2005). In PGRP-S and all 
short PGRPs examined this helix is preceded by a strand. In the PsiPred prediction of 
Patient 6’s protein, the preceding strand is missing, even though the mutation is not in 
this area. Indeed, significant secondary structural changes are predicted in Patient 6. 
This is questionable. The mutation is the second amino acid in a strand. Asparagine 
and Serine are both short polar amino acids are classed as turn and bend admirers 
(Malkov et al, 2005). The amino acid substitution should therefore not disrupt the 
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secondary structure. However, secondary structure can only be accurately assessed by 
circular dichroism spectroscopy.  
 
The Swiss PDB viewer can be used to analyse the effect of alternate residues on the 
intramolecular contacts of a molecule, as well as to determine whether the 
substitution is viable (Guex and Pietsch, 1997). Asparagine 75 is next to tyrosine 74, 
a potentially peptidoglycan contacting residue. It is therefore also situated in the 
peptidoglycan binding cleft. What is overwhelmingly clear is that the intramolecular 
distance between residue 74 and 75 is decreased. The mutant residue may therefore 
be a steric hindrance in the binding of residue 74 to peptidoglycan. Furthermore, the 
serine residue substitution results in the formation of hydrogen bonds with isoleucine 
107 and glycine 108 that were not there before. This could also have a potential 
negative effect by inducing rigidity in the molecule that may affect its ability to bind 
peptidoglycan.   
 
The changes to the protein brought about by the mutant residue are not due the 
residue itself, but rather due to its interplay with its neighbouring residue. As it is 
only one peptidoglycan binding residue, it is possible that the overall capability of the 
mutant protein to bind peptidoglycan will not be negated, but the protein will be 
functional, albeit with a reduced capability to bind peptidoglycan.  
 
4.6 Antimicrobial activity of PGRP-S 
 
All PGRPS function as dimers (Lu et al, 2006). This is not completely surprising as 
Drosophila PGRPs undergo ligand induced dimerization (Mellroth et al, 2005). The 
nature of these dimerization reactions is not completely understood. The preferential 
heterodimerization of PGRP I α and β where co-expressed (Lu et al, 2006) raises the 
question, how similar must PGRPs be in order to form dimers? Would it be possible 
for human PGRP-S and short PGRPs from Drosophila to interact, dimerize, or even 
form a functional complex? 
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The pull down assays, which allowed crude Drosophila protein to interact with 
PGRP-S fusion protein immobilized on a GST affinity matrix, did not yield any 
interacting proteins. The reason for this could be threefold. Firstly, it could be that 
PGRP-S from humans and all the short PGRPs from Drosophila could simply not 
interact. The proteins may just be too evolutionarily distinct to form functional 
complexes or complex at all. Werner et al, when describing the Drosophila PGRP 
family aligned several PGRPs across different species. Several residues were 
conserved but the primary structures of the proteins were not strikingly similar. As 
the dimers are disulphide linked, it is possible that these differences in primary 
structure account for the inability to interact.  
 
Secondly, the lack of interaction may be a function of the environment the proteins 
were allowed to interact in. The column may not be the appropriate medium and 
perhaps does not represent the physiological conditions that would have allowed the 
interaction to take place. The reaction may take place in vivo, but not in vitro. This 
can be tested by transfecting Drosophila S2 cells with a fusion tag and a eukaryotic 
promoter and subsequently purify any resultant complexes with affinity 
chromatography.  
 
The recombinant protein in this experiment did not form inclusion bodies as it did in 
previous experiments. The protein may therefore be incorrectly folded. Furthermore 
in studies that examined the activity of PGRP-S, the protein was produced in a 
eukaryotic system (Cho et al, 2005, Lu et al, 2006). The non-functionality of the 
protein is highlighted by the complete absence of antibacterial activity, even when the 
reaction is supplemented with divalent cations (Wang et al, 2007). It is not 
inexplicable that the protein has no antibacterial activity as N-glycosylation is 
described as an essential post-translational modification required for activity, as 
glycosylase complete negates antibacterial activity (Lu et al, 2006). This study 
demonstrates the lack of activity of a non-glycosylated version of the protein. 
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The most likely scenario, however, is that the entire PGRP protein, i.e. the signal 
peptide and mature peptide, was cloned. As with many antibacterial proteins, such as 
the Cathlecidins, the proteins appear to be inactive until the protein is processed. On 
initiation of the project, PGRPs were not classed as antibacterial proteins, and the 
signal peptide was classed as a putative signal peptide. To be able to perform this 
experiment accurately, the following steps have to be performed. Firstly, the mature 
peptide only needs to cloned in a eukaryotic system. Once the mature peptide has 
been purified, a glycosylase treated protein preparation can be used as a control to 
confirm the necessity of N-glycosylation for activity. To examine the effect of the 
mutation observed in Patient 6, site directed mutagenesis can be used to induce the 
mutation, and the mutant protein can then be cloned, overexpressed and purified and 
used in activity studies and compared to the activity of the wild type protein. 
 
Although PGRPs are unique because they are N-glycosylated, they are not the only 
glycosylated proteinacious antimicrobial agents. O-glycosylation is a post-
translational mechanism that is found, usually, in proline rich peptides. Drosocin 
from Drosophila, lebocin from Bombyx mori, formaecin from ants, diptericin from 
Anopheles gambiae and pyrrhocoricin from Pyrrhochoris apterus are all O-
glycosylated peptides (Otvos, 2002).  It is proposed that membrane permeabilization 
is not the primary mode of action of glycosylated peptides as the kinetics of 
membrane permeabilization for pyrrhocoricin, drosocin and formaecins is slow and 
usually requires hours of contact between the peptide and the micro-organism 
(Andreu and Rivas, 1999). These AMPs are proposed to work by binding DnaK and 
subsequently interfering with the bacterial protein folding mechanism, as this method 
has been demonstrated by pyrrhocoricin (Kragol et al, 2001). Although it has been 
demonstrated that the murine PGRP homologue Tag7 forms a cytotoxic complex 
with Hsp70 (Saschenko, 2004) it is unlikely that PGRP-S may function in the same 
manner, as pyrrhocorin is a 20-mer peptide (Cociancich et al, 1994), and therefore 
able to enter the nucleus and disrupt the translation machinery, while the 42kDa 
PGRP-S monomer would be too large to function in a similar manner. 
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4.7 Alternate splicing of PGRP-S 
 
Northern blot analysis of human PGRP expressing tissues showed that different 
splice variants exist as transcripts of different sizes were found in different tissues.  
PGRP-S expressed in the bone marrow exists as 1.4kb, 0.9kb and 0.5kb 
transcripts.1.4 and 0.9kb transcripts exist in peripheral blood leukocytes and a 0.9kb 
transcript in the foetal liver (Liu et al, 2001). No studies have been reported on the 
functionality of the products of the splice variants. When cloning procedures from 
PGRP-S has been described it is never mentioned what size transcript was used. 
Furthermore, although polymorphisms have been found in what is described as the 
promoter region, there is nothing published about human PGRP-S promoters.  This 
may suggest that there is a degree of cross promoter usage, although this has not been 
examined.   The field of PGRP-S regulation is therefore an unexplored one.  
 
The porcine PGRP-L isoforms are created by alternative splicing. These isoform play 
a role in the regulation of β-defensin in the pig (Sang et al, 2005). It could therefore 
be useful to determine whether the alternate splice variants of PGRP-S result in 
different proteins. Furthermore no reports have been made about the regulation of 
splice variation. It is possible that RNA editing may be one such regulation factor.  
 
 
4.8 RNA editing  
 
All samples sequenced from genomic DNA have a C-allele at position 80. The 
mRNA sequence, however, has a T-allele in the same locus . This is confirmed by all 
the databases used to obtain genomic and mRNA sequences. This particular change 
could represent an RNA editing event. RNA editing has been reported in eukaryotes 
ranging from protozoans (Benne et al, 1986), houseflies and German cockroaches 
(Xu et al, 2006) to mice (Powell et al, 1987; Sommer et al, 1991) and humans (Gott, 
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2000). In humans, RNA editing contributes to antibody diversity (Miramatsu et al, 
2007). 
 
A basic RNA editing event is the deamidation of Cytosine resulting in a Uracil 
substitution in the transcript. Typically, this affects translation and may cause an 
amino acid substitution, the introduction of a termination codon or a new reading 
frame due to the introduction of a new start codon (Samuel, 2003). The CCC to TCC 
change is a synonymous mutation. This is not unheard of, but is not as common as 
substitutions which induce a change (Gott and Emmerson, 2000). This silent change 
could have other effects besides a translational change. It may change the RNA 
structure, or, more importantly for PGRP-S it may affect the RNA splicing allowing 
for the selection of alternative splice sites. This C to T substitution from the genomic 
DNA to mRNA may represent a mechanism for the production of splice variants. 
This is a completely unexplored field and could potentially yield important 
information on the functionality of PGRP-S.   
 
4.8 Future directions  
 
It is clear that there are still many potential areas of study in the genetic diversity and 
functioning of PGRP-S. It would be advised to confirm the existence of the mutation 
in Patient 6 with further rounds of PCR closer to the region of interest.  The 
polymorphism at mRNA position 27 and 110 can be further genotyped to determine 
whether these polymorphisms are diseases associated. 
Most interestingly from a genetic point of view is to examine promoter and intronic 
variation, as intronic variation appears to be more common than polymorphisms in 
the coding region. It is possible that potential PGRP dysfunction may be as a result of 
aberrant splicing and regulation rather than protein dysfunction as not much variation 
ahs been reported in the protein itself. 
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This study has demonstrated the importance of glycosylation for the functioning of 
PGRP-S. The ideal set of experiments to perform therefore would be to produce the 
protein in cell culture and determine proteins that interact in vivo. Furthermore, it 
would be useful to know which human proteins PGRP-S interacts with. Site directed 
mutagenesis of the crucial peptidoglycan residues would demonstrate their true value 
in the protein. 
 
Although the sample size of this study is too small to draw statistical conclusions, 
there appears to be a trend that the protein does not display much genetic variation, 
and that the Sub-Saharan African population does not differ from the rest of the 
population in terms of this protein. The conservation of this protein may highlight the 
immunological significance of the protein.  
 
4.9 Conclusion  
 
As with bovine PGRP-S, there is a very low frequency of variation in the coding 
region of the protein, and even less variation in the protein. The variation seen in the 
Southern African population does not vary tremendously from the trends seen in 
Europeans and Asians. The high degree of conservation of the PGRP protein within 
mammals and human populations suggest that the molecule plays a critical role in 
normal immune functioning. At present there is not enough data to suggest am 
association between PGRP, HIV and tuberculosis. However, there are still many 
research questions about the protein that can be asked, particularly with the recent 
literature associating the protein with clinical diseases.  
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APPENDIX 
I) ETHICAL CLEARANCE, SUBJECT AND PATIENT INFORMATION  
Subject Information Sheet 
Hello 
We are Drs Ntwasa and Sarkin and we are doing a study to see why certain people are 
prone to infection by TB and HIV. This study may benefit medical practice in the 
future because it could contribute to our understanding of how we respond naturally 
to infections and how we can devise means to protect ourselves from germs. To do 
this we need a small amount of blood from you (10ml – about two teaspoons). This 
blood will then be examined by our team of researchers. We will only use your blood 
to test for the differences or variations in the peptidoglycan recognition protein or 
PGRP gene. These variations may affect the function of an important cell component 
called Toll. Toll and PGRP are present in all human beings but slight differences in 
these cell components may occur from person to person. We would like to investigate 
this because these slight variations may prove to be useful in identifying people who 
are prone to developing HIV and TB infections. 
 
The results of tests done on your blood sample will be kept confidential and will only 
be used by this select group of researchers. The results of these test are still 
investigational and therefore at this stage cannot be used to alter your treatment. 
There will be no personal benefits to you. You are free to choose whether you wish to 
participate in this study. You are not under any pressure to take part. You may also 
withdraw at any time you wish if you feel you no longer want to be part of the study. 
 
The removal of blood will be done during routine examination in the hospital. This 
means an extra tube will be taken when other samples are done as part of care in the 
hospital. There is no risk to this procedure, only a little pain (the prick of a needle) 
and perhaps a small bruise. The procedure will be performed by a qualified hospital 
staff member. 
 
We will also ask you to complete a short questionnaire which asks simple questions 
such as your language, place of birth and that of your family. 
 
We thank you very much for showing interest 
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PATIENT QUESTIONAIRE 
 
NB: A translation is possible when required 
 
We are studying cells in patients with infections. This may help science to find out 
why certain patients have these diseases. Your doctor will continue to explain the 
nature of your medical conditions. All information will be strictly confidential. 
 
Patient Number           e.g. 1-50 
 
 
YOU 
Place of birth                                  Province                                          Country 
Home language 
 
 
YOUR PARENTS 
 
Your mother                Your Father 
Place of birth                 Place of birth____________________ 
Province  Country                        Province  Country________ 
 
 
YOUR GRANDPARENTS 
 
Your mother’s mother              Your Father’s mother 
Place of birth                 Place of birth_____________________ 
Province  Country                        Province  Country________ 
 
Your mother’s father   Your Father’s father 
Place of birth                 Place of birth____________________ 
Province  Country                        Province  Country________ 
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II) MATERIALS AND METHODS 
 
Table7: Reagents for DNA techniques: 
 
50X TAE:                   2M Tris, 5.7% glacial acetic acid, 0.5M EDTA pH 8.0 
Solution 1:                  50mM glucose. 25mM Tris, 10mM EDTA pH 8.0                                        
Solution 2:                  0.2M NaOH, 1% SDS (w/v) 
Solution 3:                  3M NaCH3COO 
Ethanol acetate:        96% (v/v) absolute ethanol, 4% (v/v) 3M NaCH3COO 
 
 
Table 8: Reagents for Protein Electrophoresis 
SDS-PAGE sample buffer: 0.225M Tris-Cl (pH 6.8), 50% glycerol, 5% SDS, 05%   
                                             bromophenol blue, 0.25mM DTT 
 
SDS-PAGE electrophoresis buffer:   0.5M Tris Base, 1/92M glycine, 0.5% SDS 
 
Coomassie blue stain:  0.1% Coomasie blue R-250 (w/v), 10% acetic acid, 40%  
ethanol 
 
Destain solution:                 40% methanol, 10% acetic acid 
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Table 9: Reagents for protein extraction and purification 
Cell lysis buffer: 25 mM Tris, 150 mM NaCl, 0.2% SDS, 0.5 mM 
PMSF (Sigma), 1 µg/ml aprotinin, 4.0 mM 
Pefabloc (Roche) 
RIPA buffer: 1x PBS, 1% Nonidet P-40, 0.5% sodium 
dioxycholate, 0.1% SDS 
GST purification kit: BugBuster protein extraction reagent, and 10, 
000 units benzonase 
GST bind wash buffer (10x):43 mM Na2HPO4, 14.7 mM KH2PO4, 1.37 M 
NaCl, 27 mM KCl pH 7.3 
GST elution buffer:             500mM Tris-HCl pH 8.0100mM glutathione 
GST mag agarose beads: 50% slurry, 0.05 M Na2HPO4 pH 7.5, 0.15 M 
NaCl, 0.1 M NaN3 
Protease inhibitor stocks 10 mg/ml PMSF (Sigma), 20 mg/ml Pefabloc 
(Roche), 1mg/ml Apportionin (Roche) 
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Table 10: Lists of kits and suppliers 
KIT  SUPPLIER 
CAT 
NUMBER 
QIAmp DNA Blood midi Kit  Qiagen  51183 
QIAmp RNA Blood mini Kit  Qiagen  52304 
Acess RT-PCR kit Promega A1250 
p-GEM-T Easy Vector system  Promega A1360 
GenElute™ Gel Extraction kit  Sigma NA1111 
SyBr® Gold nucleic acid stain  Invitrogen S-11494 
BL21(DE3)pLysS competent cells Novagen  69451-3 
GST-Bind™ Purification kit Novagen  70794-3 
GeneRuler™100 basepair plus Fermentas SM0321 
PageRuler™ Prestained protein ladder Fermentas SM0671 
 
 
Table 11: List of specialised equipment 
GeneAmp® PCR system 2004 Applied Biosystems 
Dark® reader Clare chemical research 
G: Box Chemi XL gel documentation system Syngene 
GS-800 calibrated scanning densitometer  Biorad 
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Figure 21:  pGEM®-T Easy Vector circle  map and sequence reference points. 
 
T7 RNA polymerase transcription initiation site   1 
multiple cloning region      10–128 
SP6 RNA polymerase promoter (–17 to +3)    139–158 
SP6 RNA polymerase transcription initiation site   141 
pUC/M13 Reverse Sequencing Primer binding site   176–197 
lacZ start codon       180 
lac operator        200–216 
β-lactamase coding region      1337–2197 
phage f1 region       2380–2835 
lac operon sequences       2836–2996, 166–395 
pUC/M13 Forward Sequencing Primer binding site   2949–2972 
T7 RNA polymerase promoter (–17 to +3)   2999–3 
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Figure 22: pET-41a Vector circle  map and sequence reference points 
 
T7 promoter       1167–1183 
T7 transcription start      1166 
GST•Tag coding sequence     436–1095 
His•Tag coding sequence     397–414 
S•Tag coding sequence     310–354 
Multiple cloning sites 
(PshAI-XhoI)       174–265 
His•Tag coding sequence     150–173 
T7 terminator       26–72 
lacI coding sequence                1574–2656 
pBR322 origin      3850 
Kan coding sequence      4559–5374 
F1 origin 5474–5921 
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URLs for databases: 
Reference sequences and data mining 
BLAST:  http://www.ncbi.nlm.nih.gov/blast/Blast.cgi 
Clustal W: http://www.ebi.ac.uk/Tools/clustalw2/index.html 
SNP verification 
dbSNP: http://www.ncbi.nlm.nih.gov/sites/entrez?db=snp&cmd=search&term= 
Ensembl: http://www.ensembl.org/index.html 
jSNP: http://snp.ims.u-tokyo.ac.jp/ 
SNPer: http://snpper.chip.org/. 
UCSC genome brower: http://genome.ucsc.edu/ 
 
Proteomics analysis 
RCSB protein database: http://www.rcsb.org/pdb 
PsiPred secondary structure prediction server: http://bioinf.cs.ucl.ac.uk/psipred/ 
Swiss PDB viewer: http://www.expasy.ch/spdbv/ 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 111 
III) Results 
 
>ref|NT_011109.15|Hs19_11266:c18795026-18790173 Homo sapiens chromosome 
19 genomic contig, reference assembly 
AGGCTTGGACCTGGGGGAAGGAAGTGTTTTTAAAATGGGTAGCTTTGTTACCTCAGTCCTTGCGGGGAGA 
AGATGTGCCAATGCCCCGGGCCTCTGCGATGTAAGTTCCTGTTGAGTTGTTCAATGTTCCACTGAGAGGA 
GAGACAAGCAGGACCGGGATCCCGGCCCCGGGTCTTCCAGAAACGGCGGGGCGAAGCGCCCAGGGGCCTG 
TGCGTCCCTCCCTGCTGAGCGAGGGGGCCTGTCATTGCCGTGGGCGTGACCCAGACCCCAACCACAGTGC 
ATCCCGCCCTGGCCCAGCCAGAGAAGGAAGCTGAGTCTGGGGTCTGCTGGGCCAGCAGGAAGTCCCAGCA 
GGGTGTGAAGCAAGACTTTCCGGGCCACTCCTGGAATCCCCCAGCAGATAAAGGCGGCCCCTCCACCGGG 
CGCTCCTAGCGGTCTCCCGGACCCTGCCGCCCTGCCACTATGTCCCGCCGCTCTATGCTGCTTGCCTGGG 
CTCTCCCCAGCCTCCTTCGACTCGGAGCGGCTCAGGAGACAGAAGACCCGGCCTGCTGCAGCCCCATAGT 
GCCCCGGAACGAGTGGAAGGCCCTGGCATCAGAGTGCGCCCAGCACCTGAGCCTGCCCTTACGCTATGTG 
GTGGTATCGCACACGGCGGGCAGCAGCTGCAACACCCCCGCCTCGTGCCAGCAGCAGGCCCGGAATGTGC 
AGCACTACCACATGAAGACACTGGGCTGGTGCGACGTGGGCTACAAGTGAGTGTGGCAGGGGGGCACGGG 
CTGGACTGGGGATCCCAGAGGCAAAGGTGTGCAAGTGCCCGCCAGCGGGACCATTTCTAGGCCTGGTGCT 
GAGGCCACCTGGCTGACACCCTGAGCAGCTTACTGAACCTCACAAGGTCATTTCTTCCTCGGGTCACCAC 
GTGGGCCGGGGCAGGTGCTCACAGCACAAAGATGCGTGAGAAGGGGGGATGGGCTGAAATCCAAGCCCCG 
CTCCCGCTCCCGGGAAGAAGGGGCAGGCTTTGCCTAACACACACCAAGGTGTCCGCGACGCCTTATGAAG 
GCGCCCCTTCCTGATGCCTGGTGCCTTTGTTAGGAGGCGGAAAACCAGGCTGACTCAGTGCGGAGCTGGG 
TTCCAGGGTCAGCTCATCTTATTGCTGGCTGAGGCCTGGGGCGGGTCCTCCCGGCTTCAGCTTCCTCCTC 
GGCAAAGTCAATGGAATCGCGGCCCATCTGCTCCTTATATGAGCCAATACAGGCAAAGCACCTAGGAACT 
GCCTGGCACACGGGGGCCCGCAAAGCCACGGGCTATTACCATTAGGCACCTACTATGTGCCAGGCAGTGT 
GCCAGATGTGGCATGGAGAACGGTGCCACTCTAGCCTCCTGGGGTTGAAAGACCAGCAGGGAGAAACAAG 
CCAAGGCCACAGGTGAATTCAGACGGTGATAGAGGCGATGGATAAAAGGAAAGAGGTGAGGGAGGGTGAC 
CTCAGGCTGGGACCAGACCCACACAGGCTCCTTGGAAGGGTGGGGCAAGGGAAAGCCTCCCTGAGAGTGG 
CTGCCTTGGCTCTGGGATGGGGGAGCAGACAGAGGCCTGCAGGTGGCAGGGGGTGCTGGGGGCAAAGCCA 
ACGGGGTTGAGTGGGCGGGTCCTGTGGGAAGGACAGGGTGGCTGAACACAGCCGGGCGAGCGGAATGAAA 
TGAGGAAAGGGCAGGACCAGGCAGGGCTTTGTGGACCACAGTGAGGACTGTAGCTTTTACTCCGAGATGG 
GAGCCATGGGAGGCTTCCCCCCGCAGAGCAGGGACCAGGGCTAGTGTAGGTACAAGAGACTCCCTCTGGC 
TGCTGTGGGGAGAACAGACTGTAAGGGGTGCCGGCTGAAGCAGGCTGAAGCAGGTCCGGGGCCACGCCTA 
CCAGCTACCTCCTCCTTAGAATGGGCTGCAGTCCAGCCTGACGGTTTCCACAGGGAGGGAACTTTCAATC 
CTGCAGGCTCTCAGACCCAGGTAAGCATCAGAATCTCCTGCAGAGCTTATTGGAGGAACATGCAGGTCCC 
CAGAGACCACTTCAATAGACCCCACCCAGGGGACACATGTTCTCAGGACCTCCTAAGGCTGTGTCTCACA 
CACACACACACACAAAACCCACCCAGAGAAGTCTAGAAGTGTCCAAAGGTATTCCCAGCCCTTCCAGTTC 
AAGATTTTATCAAAGACTCCAACTTCAACATTTTGTTTCCAAGACTCAGGCGCTCTGATCCTAAGTGTTC 
CCATGAGGTCACGAAGGCCCGAGCCTCGGGTCCACATCACCACATACAGAAGCAGCCGCTGTCTGGCCCT 
CAGCTTTTAGGATTCCGAATCTGGTTCTAACGTTCTGAATCCCCTTTCCATGTCACGTCACCTTCTCTCT 
CTGAGCCTCGTTTCTTCACCTGTAAATGGGGCTTCTGACTGTACCCGCTTGGCGATGGTGGCTGAGGTTT 
CAATGAGATGCATTCATGCAACAAATGACCAGGGAGAACCAACCACCCCCGACCCCAGCACCATCATGCC 
AGGCTCCGGGAATATGGCAGGGCCATAACCAGCCAGTCCCAGCAGCCAGCATCACCAGCAGGGCCATAAC 
CAGCCAGTCCCAGCAGCCAGCATCACTGGGGCCAGATTCTGGGAGCTGGCTTCCTAAGCAGCAGATTCGG 
GACTCAAGATTCGGAAGTTCCGACATTCTGTGCGTCATTAATGACACTGTGAGCGCGGGGGCTGAGTTGG 
CACATACTGCAGCTCCAAGGCACTGATCTTCTAGTTCATTCCCATTTGCCAAGTCAGACACGCTCAATCA 
GATGTGCTGAATGAATCAGCCTTAAGGATCTGCTGCCAGGCTTGGGAACCTCAAAGAGGCAGGTGCTGGG 
GCTCCAGGGTCGGTATCTGGTTACGACCCCAACTTTGAGTCTGTGATCCTGTCCCCCAGTGGACCCCGAG 
GGCAGGAAGCAAGCTGGGGCAAAGGCAGAGTTCTGAGAGGCAGGGGGCTCTGAGTAGCTTGTACAAATTA 
TGTCGCTTTCTGAGTCTCTGCTCTCTCTGCTTAAGATGAGGATGATAAGAGTCCCTGCCTTGGCTGGGCA 
CGGTGACTCATGCTTGTAATCCCAGCACTTTGGGAGGCCAAAGGCGGGCAGATCACCTGAGGTCGGGAGT 
TCGAGACCAGCCTGGCCAACATGGTGAAACCCCATCTCTACTAATAATACAAAAATTAGCCGGGTGTGGT 
GGCTCATGCTTGTAATCCCAGGTACTCAGGAGGCTGAGGCACGAGAATCACTTGAACCCAGGAGGCAGAG 
GTTGCGGTGAGCTGAGATCACGCCACTGCACTCCAGCCTGAGCAACAAGAGTGAAACCCCGTCTTAAAAA 
AAAAAAAAAAAAAAAGTCTCTGCCTCAGAGGGCTGTCCTGCAAGGATTCAGTAAAACAGGACTTCCACAA 
ATCCTCTAGGGAGGCAGGAGAGAGCAACGCACAAGATCACATGGGTGGGGACCATGGAGGCCTGGTTAAA 
AACCCCAGCTGTGCCCCAGACAGGCTGTGTGACCCCGGGGCAGGTGATTCTACCGCTCTGATTCTGTCTA 
TATAAAACGGGGGTGATAGTGACTCACAGGGTTGCTGTGAGGATGGAAAAAGGTGTATGCAGAGCTGTGC 
TTGGCACATGGCAGGGGCCCAATAAATGACCACAGTCATTGTTACTATCGTGGGAAATTAACGGGTGAGA 
AGGATGCTGGGGAAGTTGTGTGCACCACGGCAGTAACGGAGGCAGGGTGAGTGGAGGAAGGAGGAGGAGT 
CCTCCTCGGGAAACCCTCCCTCACTCATCAAGCCCCCCCACCTCCCCATGCAGCTTCCTGATTGGAGAAG 
ACGGGCTCGTATACGAGGGCCGTGGCTGGAACTTCACGGGTGCCCACTCAGGTCACTTATGGAACCCCAT 
GTCCATTGGCATCAGCTTCATGGGCAACTACATGGGTGAGTGACTGTCCAGCCAGTTGGGATGGGGGCTG 
ACACGGGGCCCTACGCTATCACTTCCCCTTCGGGGAAGCCCCTGCCTGACTCCTACCTCTGCCTCCTCCA 
GATCGGGTGCCCACACCCCAGGCCATCCGGGCAGCCCAGGGTCTACTGGCCTGCGGTGTGGCTCAGGGAG 
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CCCTGAGGTCCAACTATGTGCTCAAAGGACACCGGGATGTGCAGCGTACACTCTCTCCAGGCAACCAGCT 
CTACCACCTCATCCAGAATTGGCCACACTACCGCTCCCCCTGAGGCCCTGCTGATCCGCACCCCATTCCT 
CCCCTCCCATGGCCAAAAACCCCACTGTCTCCTTCTCCAATAAAGATGTAGCTCAAAATGTGTTCCTCAG 
CAGGTCCCACCACACACCTCCCCTCCTTCTCTCCCTCCCACAAGACCAAAGCCCTCCCACCCCTTCCCCT 
CCCAGCACTCTCCTCACTGGTGCTTGGAACCCAGAGGCCCCGGCCCTGAACCAAGACCCCGGAGATCCCA 
GCTCGAGAGCAACATCACAGCTCAGAACCCAGAGGTCTCAGGTCAGAGCCCAGGAATCAGCACCAAGGCG 
GCCGGGATGTCACCAACAGTGGGTCCTGGGGGTCCTCCTGGGCAGTGAACCACGCTGCAAGACACCTCCT 
TCCCACCACACAGCCAAAGGCATCCTGCGCAGAAACTTTGCTTGGACTCCTTTAGGGACGGGCTGCTCAC 
TACTCCTCCCAGGTCTGCCCTTGCACTGTTTAGAGAGTGTACAAGCTTTTCCTAGGCCTGAGTCCCAATC 
TGCCTCCGAGGCACAGACACACAG 
 
Figure 23: Genomic sequence of PGRP-S. Exons are highlighted in bold and primer 
binding sites indicated 
 
 
AF076483 Homo sapiens peptidoglycan recognition protein precursor 
(PGRP) mRNA, complete cds 
 
CCGGGCGCTCCTAGCGGTCTCCCGGCCCCTGCCGCCCTGCCACTATGTCCCGCCGCTCTATGCTGCTTGC 
CTGGGCTCTTCCCAGCCTCCTTCGACTCGGAGCGGCTCAGGAGACAGAAGACCCGGCCTGCTGCAGCCCC 
ATAGTGCCCCGGAACGAGTGGAAGGCCCTGGCATCAGAGTGCGCCCAGCACCTGAGCCTGCCCTTACGCT 
ATGTGGTGGTATCGCACACGGCGGGCAGCAGCTGCAACACCCCCGCCTCGTGCCAGCAGCAGGCCCGGAA 
TGTGCAGCACTACCACATGAAGACACTGGGCTGGTGCGACGTGGGCTACAACTTCCTGATTGGAGAAGAC 
GGGCTCGTATACGAGGGCCGTGGCTGGAACTTCACGGGTGCCCACTCAGGTCACTTATGGAACCCCATGT 
CCATTGGCATCAGCTTCATGGGCAACTACATGGATCGGGTGCCCACACCCCAGGCCATCCGGGCAGCCCA 
GGGTCTACTGGCCTGCGGTGTGGCTCAGGGAGCCCTGAGGTCCAACTATGTGCTCAAAGGACACCGGGAT 
GTGCAGCGTACACTCTCTCCAGGCAACCAGCTCTACCACCTCATCCAGAATTGGCCACACTACCGCTCCC 
CCTGAGGCCCTGCTGATCCGCACCCCATTCCTCCCCTCCCATGGCCAAAAACCCCACTGT 
 
 
Figure 24: mRNA sequence for PGRP-s, with areas that will demarcate into exos 
highlighted 
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DNA Sequences for mutant Patients 
>Patient 6 (HIV) 
1     GGCGCTCCTAGCGGTCTCCCGGCCCCTGCCGCCCTGCCACTATGTCCCGCCGCTCTATGC 
61    TGCTTGCCTGGGCTCTCCCCAGCCTCCTTCGACTCGGAGCGGCTCAGGAGACAGAAGACC 
121   CGGCCTGCTGCAGCCCCATAGTGCCCCGGAACGAGTGGAAGGCCCTGGCATCAGAGTGCG 
181   CCCAGCACCTGAGCCTGCCCTTACGCTATGTGGTGGTATCGCACACGGCGGGCAGCAGCT 
241   GCAACACCCCCGCCTCGTGCCAGCAGCAGGCCCGGAATGTGCAGCACTACCACATGAAGA 
301   CACTGGGCTGGTGCGACGTGGGCTACAGCTTCCTGATTGGAGAAGACGGGCTCGTATACG 
361   AGGGCCGTGGCTGGAACTTCACGGGTGCCCACTCAGGTCACTTATGGAACCCCATGTCCA 
421   TTGGCATCAGCTTCATGGGCAACTACATGGATCGGGTGCCCACACCCCAGGCCATCCGGG 
481   CAGCCCAGGGTCTACTGGCCTGCGGTGTGGCTCAGGGAGCCCTGAGGTCCAACTATGTGC 
541   TCAAAGGACACCGGGATGTGCAGCGTACACTCTCTCCAGGCAACCAGCTCTACCACCTCA 
601   TCCAGAATTGGCCACACTACCG 
>Patient 12 (HIV/TB) 
1     GGTCTCCCGGCCCCTGCCGCCCTGCCACTATGTCCCGCCGCTCTATGCTGCTTGCCTGGG 
61    CTCTCCCCAGCCTCCTTCGACTCGGAGCGGCTCAGGAGACAGAAGACCCGGCCTGCTGCA    
121   GCCCCATAGTGCCCCGGAACGAGTGGAAGGCCCTGGCATCAGAGTGCGCCCAGCACCTGA 
181   GCCTGCCCTTACGCTATGTGGTGGTATCGCACACGGCGGGCAGCAGCTGCAACACCCCCG 
241   CCTCGTGCCAGCAGCAGGCCCGGAATGTGCAGCACTACCACATGAAGACACTGGGCTGGT 
301   GCGACGTGGGCTACAACTTCCTGATTGGAGAAGACGGGCTCGTATACGAGGGCCGTGGCT 
361   GGAACTTCACGGGTGCCCACTCAGGTCACTTATGGAACCCCATGTCCATTGGCATCAGCT 
421   TCATGGGCAACTACATGGATCGGGTGCCCACACCCCAGGCCATCCGGGCAGCCCAGGGTC 
481   TACTGGCCTGCGGTGTGGCTCAGGGAGCCCTGAGGTCCAACTATGTGCTCAAAGGACACC 
541   GGGATGTGCAGCGTACACTCTCTCCAGGCAACCAGCTCTACCACCTCATCCAGAATTGGT 
601   CAC 
>Patient 15 (HIV)  
1     CTATGTCCCGCCGCTCTATGCTGCTTGCCTGGGCTCTCCCCAGCCTCCTTCGACTCGGAG 
61    CGGCTCACGAGACAGAAGACCCGGCCTGCTGCAGCCCCATAGTGCCCCGGAACGAGTGGA 
121   AGGCCCTGGCATCAGAGTGCGCCCAGCACCTGAGCCTGCCCTTACGCTATGTGGTGGTAT 
181   CGCACACGGCGGGCAGCAGCTGCAACACCCCCGCCTCGTGCCAGCAGCAGGCCCGGAATG 
241   TGCAGCACTACCACATGAAGACACTGGGCTGGTGCGACGTGGGCTACAGCTTCCTGATTG 
301   GAGAAGACGGGCTCGTATACGAGGGCCGTGGCTGGAACTTCACGGGTGCCCACTCAGGTC 
361   ACTTATGGAACCCCATGTCCATTGGCATCAGCTTCATGGGCAACTACATGGATCGGGTGC 
421   CCACACCCCAGGCCATCCGGGCAGCCCAGGGTCTACTGGCCTGCGGTGTGGCTCAGGGAG 
481   CCCTGAGGTCCAACTATGTGCTCAAAGGACACCGGGATGTGCAGCGTACACTCTCTCCAG 
541   GCAACCAGCTCTACCACCTCATCCAGAATTGGCCACACTACCGCTCCCCCTGAGGCC 
 
>Patient 27 (HIV) 
1     CCCTGCCGCCCTGCCACTATGTCCCGCCGCTCTATGCTGCTTGCCTGGGCTCTCCCCAGC 
61    CTCCTTCGACTCGGAGCGGCTCAGGAGACAGAAGACCCGGCCTGCTGCAGCCCCATAGTG 
120   CCCCGGAACGAGTGGAAGGCCCTGGCATCAGAGTGCGCCCAGCACCTGAGCCTGCCCTTA 
180   CGCTATGTGGTGGTATCGCACACGGCGGGCAGCAGCTGCAACACCCCCGCCTCGTGCCAG 
240   CAGCAGGCCCGGAATGTGCAGCACTACCACATGAAGACACTGGGCTGGTGCGATGTGGGC 
300   TACAACTTCCTGATTGGAGAAGACGGGCTCGTATACGAGGGCCGTGGCTGGAACTTCACG 
360   GGTGCCCACTCAGGTCACTTATGGAACCCCATGTCCATTGGCATCAGCTTCATGGGCAAC 
420   TACATGGATCGGGTGCCCACACCCCAGGCCATCCGGGCAGCCCAGGGTCTACTGGCCTGC 
480   GGTGTGGCTCAGGGAGCCCTGAGGTCCAACTATGTGCTCAAAGGACACCGGGATGTGCAG 
540   CGTACACTCTCTCCAGGCAACCAGCTCTACCACCTCATCCAGAATTGGCCACACTACCGC 
600   TCCCCCTGAGGCCCTGCTGATCCGCACCCCATTCCTCCCCTCCCATGGCCAAAAACCC 
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Table 7: Table of individual patient genotypes 
Sample Status 27 80 110 320 651 
Patient 1 HIV/TB CA CC GG CT CC 
Patient 3 control CA CC GG CC CC 
Patient 4 control CC CC GG CT CC 
Patient 6  HIV CC CC GG CT CT 
Patient 7 HIV CA CC GA CC CC 
Patient 10 HIV/TB CA CC GG CC CC 
Patient 11 HIV/TB CA CC GG CT CC 
Patient 12 HIV/TB CC CC GG CC CT 
Patient 15 HIV CA CC GG CT CC 
Patient 16 HIV/TB CC CC GG CC CC 
Patient 18 HIV AA CC GG CC CC 
Patient 24 HIV CA CC GA CT CC 
Patient 25 HIV CA CC GG CC CC 
Patient 27 HIV CA CC GA CT CC 
Patient 29 HIV/TB CA CC GG CT CC 
Patient 30 HIV/TB CC CC GG CC CC 
Patient 31 control CA CC GG CC CC 
Patient 34 control CA CC GA CC CC 
Patient 36  control CA CC GG CC CC 
Patient 43 HIV CC CC GG CC CC 
 
 
 
 
 
 
 
 
 
